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Use of Antidepressant Medications and the Subsequent Course of Depressive 
Symptoms among Older Adults
Janet Abou, Thomas Gill, Lisa Barry. Yale University School of Medicine-New Haven, 
CT
Antidepressant  medications  are  commonly  prescribed  for  older  adults  with 
depressive symptoms who may not have a major depressive disorder. Yet, the effect of 
antidepressants on depressive symptoms over time in this population is largely unknown.
We  sought  to  determine  whether  the  use  of  antidepressant  medications  is 
associated with a reduction in the severity of depressive symptoms over time.
Participants included 754 community-dwelling adults, aged 70+ years, who were 
followed at 18-month intervals for 90 months. Depressive symptoms were assessed using 
the 11-item CESD scale, with a higher score indicating worse depressive symptoms. A 
linear  mixed  effects  model,  adjusted  for  demographic  features,  number  of  chronic 
conditions,  cognitive  status,  and  physical  frailty,  was  used  to  evaluate  the  effect  of 
antidepressant use on change in depressive symptoms score over time. In addition, among 
persons  with  clinically  significant  depressive  symptoms (i.e.,  CESD score >=20),  we 
evaluated whether antidepressant use was associated with a transition to a non-depressed 
state (CESD score <20) using a Generalized Estimating Equations (GEE) model.
At baseline, participants taking an antidepressant (n=75) had higher mean CESD 
scores than those not taking an antidepressant (15.1+ 9.2 vs. 8.5+8.3; p<0.001) and were 
more likely to be female (p<0.001). Average unadjusted CESD change scores ranged 
from -3.4 to 1.7 and 0.4 to 1.5 among those taking, and not taking, an antidepressant, 
respectively (for the different 18-month intervals). Adjusted CESD scores worsened, on 
average, for participants taking an antidepressant as compared with those not taking an 
antidepressant.  These  differences  were statistically  significant  between baseline  to  18 
months  (p=0.03),  36  to  54  months  (p=0.02)  and  72  to  90  months  (p=0.01).  The 
longitudinal findings indicated that CESD scores worsened by 2.2 points, on average, 
among  participants  taking  an  antidepressant  as  compared  with  those  not  taking  an 
antidepressant, although this difference was not statistically significant (p=0.14). Among 
participants with clinically significant depressive symptoms, use of antidepressants was 
not associated with transitioning to a non-depressed state (OR=0.85, 95% CI 0.5-1.4).
Our findings raise concerns about the effectiveness of antidepressant medications, 
as prescribed in clinical practice. Additional research is needed to better understand the 
real world use and benefit of antidepressants among older adults.
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1.1. Depression in Older Adults
Major depression, as defined by the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV), affects 1-2% of community-dwelling older adults.1  However, 6-
18% of older adults experience clinically significant depressive symptoms that do not 
meet the DSM-IV criteria for major depression.2-6  These clinically significant depressive 
symptoms are commonly referred to in the literature as elevated depressive symptoms or 
subthreshold  depression,  or  subsyndromal  depression.7-11  A  number  of  longitudinal 
studies have found that depressive symptoms are associated with worse health outcomes 
in  older  adults.   For example,  elevated  depressive symptoms have been shown to be 
associated with increased mortality12, 13 and comorbid conditions such as coronary heart 
disease14 and type  2 diabetes.15,  16  Depressive symptoms also have been found to be 
associated with decreased cognition, disability in activities of daily living, and decreased 
activity.14, 15, 17-19  The risk for major depressive disorder and suicide also increases among 
older  adults  with  elevated  depressive  symptoms.11,  20  Furthermore,  greater  healthcare 
costs are accrued by older adults with elevated depressive symptoms.21-23  Despite the 
public health significance of elevated depressive symptoms among older adults, however, 
this condition is still widely underrecognized and undertreated.
1.2. Classification of Depression
Depressive disorders are classified in many ways.  Clinically relevant depressive 
disorders are defined by the DSM-IV and there are 3 main categories for depression 1) 
Major depression, 2) Dysthymia and finally 3) Minor depression. Major depression as 
defined by the DSM-IV as five (or more) of the following symptoms present during the 
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same 2-week period and represent a change from previous functioning; at least one of the 
symptoms is either depressed mood or anhedonia; 1) depressed mood, 2) anhedonia, 3) 
significant  weight  loss when not dieting or weight  gain,  4) insomnia  or hypersomnia 
nearly every day, 5) psychomotor agitation or retardation, 6) fatigue or loss of energy 
nearly  every day,  7)  feelings  of  worthlessness  or  excessive  or  inappropriate  guilt,  8) 
decreased concentration, 9) recurrent thoughts of death.  Dysthymia is characterized by 
an overwhelming yet chronic state of depression, exhibited by a depressed mood for most 
of the days, for more days than not, for at least 2 years. The symptoms are the same as 
those described for major depression.  Elevated depressive symptoms is not a clinical 
diagnosis however it is made using screening tools for depression.  The literature will 
occasionally refer to elevated depressive symptoms as depression or minor depression 
since the screening tools used are sensitive for detecting depression.  However, without a 
DSM diagnosis we will refrain from assigning a clinical diagnosis to elevated depressive 
symptoms.
1.3. Underdiagnosis and Undertreatment of Depressive Symptoms
1.3.1. Underdiagnosis 
Research suggests  that  major  depression and elevated depressive symptoms in 
older adults are more likely to be diagnosed and treated by primary care physicians than 
by other specialists, such as psychiatrists.24  It also has been indicated that older adults 
prefer  to  be  treated  by  their  primary  care  physician  for  problems  related  to  mental 
health.25 However,  depression  in  older  adults  is  frequently  underdiagnosed  and 
undertreated in the primary care setting.26
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Patient-related factors may contribute to the underdiagnosis and undertreatment of 
depression  in  this  population.   Patients’  fear  of  stigmatization  of  having  depression, 
discomfort  with  medical  treatment,  belief  that  depression  is  part  of  normal  aging, 
physical illness, and grief may delay or prevent older adults from seeking antidepressant 
treatment.27,  28 29-31  Givens et  al.32 conducted a qualitative study and found that older 
adults resisted antidepressant treatment due to four main reasons; 1) fear of addiction, 2) 
not viewing depression as a medical disease, 3) reluctance to prevent natural sadness, and 
4) poor experience with prior medication. It is also possible that impairments in patients’ 
vision,  hearing or cognitive function might  delay physicians’  ability to recognize and 
diagnose  depression  because  these  impairments  affect  communication  between  the 
patient  and physician.33,  34   In addition,  older  adults  are  more  likely to give socially 
desirable  responses  to  physicians’  inquiries  about  mood  as  compared  with  younger 
adults,33,  35 thereby making  it  more  difficult  for  physicians’  to  detect  the presence  of 
depressive symptoms.
Several physician  factors  also  have  been  shown  to  contribute  to  the 
underdiagnosis  and  undertreatment  of  depression  in  older  adults.   Physicians  may 
mistakenly  think  that  persistent  depressive  symptoms  are  an  acceptable  response  to 
aging-related illnesses or conditions.36  For example, symptoms of depression are often 
mistaken for irreversible dementia.37  Similarly, depression may be incorrectly considered 
as  an  inevitable  response  to  loss  of  social  support/socialization38 39 and  to  financial 
hardships that often accompany aging, rather than to a potentially treatable and reversible 
condition.1  Lack of confidence when diagnosing and treating depression among older 
adults also may contribute to the underrecognition and undertreatment of depression.  In 
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one study of 153 internists,  only 55% and 35% felt confident diagnosing and treating 
depression, respectively, among their older adult patients.40  Another potential problem is 
that physicians do not have enough time to establish rapport and to interview patients 
regarding  nonmedical  life  issues,  which  could  provide  insight  into  distinguishing 
depression from other medical illnesses.40
Detection of depression can be accomplished through several formal screening 
tools available for use in older adults.  These include the Center for Epidemiologic Study 
Depression Scale (CESD), Geriatric Depression Scale (GDS), or two simple questions 
about mood and anhedonia ("Over the past 2 weeks, have you felt down, depressed, or 
hopeless?" and "Over the past 2 weeks, have you felt little interest or pleasure in doing 
things?").41-43  Evidence  suggests  that  administration  of  a  screening  tool  can improve 
recognition  of  depression in  older  persons.   One study,  in  an emergency department 
setting, found that use of a screening tool such as the GDS identified 60% more cases of 
depression than physicians’ assessments alone.44  However, despite these prior findings 
and a recommendation by the U.S. Preventive Services Task Force (USPSTF) to screen 
adults for depression,45 less than a third of physicians use a systematic screening device to 
evaluate depressive symptoms.46  Consequently,  there is ample opportunity to improve 
primary care physicians’ recognition of depressive symptoms in older adults.  
1.3.2. Undertreatment
Even when depressive symptoms are diagnosed in older adults,  failure to treat 
depressive symptoms is common.24  Luber et al. found that only one-third of the older 
outpatients who were diagnosed as depressed by their primary care providers received 
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antidepressant treatment.30  In a study conducted in London, these investigators found 
that only 38% of patients mentioned their symptoms to their primary care physician; and 
of those found to have elevated depressive symptoms, only  14% were prescribed an 
antidepressant, while 24% were prescribed a hypnotic.47  In a study by Callahan et al.48, 
less  than  half  of  older  adults  identified  as  having  depressive  symptoms  received 
antidepressant treatment.
1.4. Rates of Antidepressant Use Among Older Adults
Among older adults who are treated for depressive symptoms, antidepressants are 
the most common form of treatment.  In a survey of 215 physicians,  many physicians 
were uncertain about the benefits of psychotherapy for older persons.  For example, only 
57% thought  that  psychotherapy  was  as  effective  in  older  adults  as  it  is  in  younger 
persons.49  According to a cross-sectional study, only 1% of older adults have visited a 
psychotherapist.50  A  meta-analysis  evaluating  the  efficacy  of  cognitive  behavioral 
therapy (CBT) in  older  adults  found that  it  was  efficacious  when compared  to  those 
waitlisted for psychotherapy.51
When antidepressants were first introduced, the first line therapies were Tricyclic 
Antidepressants  (TCA’s).   However,  side  effects  from  these  medications  can  be  of 
concern in older adults because they can cause difficulties with memory and dizziness, 
and they increase the risk of falls.52  Selective serotonin reuptake inhibitors (SSRI’s) are 
now considered the first line therapy for depression and depressive symptoms in older 
adults as they have been shown to have fewer side effects and are better tolerated than 
TCAs.52  In 1993, 9.6% of the antidepressants prescribed were SSRI’s, while in 1997, 
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45.1% of the antidepressants prescribed were SSRI’s, as determined through prescribing 
records for all adults.53, 54
Antidepressant prescribing and use has increased modestly in older adults during 
the last decade.  The rate of antidepressant use in older adults, regardless of depression 
status, between the 1980’s and the early 1990’s ranged from 2.3% to 9.3%.53, 55  In the late 
1990’s through the present, the rate of antidepressant use in older adults ranged from 
8.1% to 11.5%.53,55, 56  The increased use of antidepressants in the past decade is attributed 
to  the  availability  of  the  SSRI’s  and increased  knowledge and familiarity  with  these 
medications by prescribing physicians.57  Nonetheless, even with the wider availability of 
SSRI’s, older adults continue to be undertreated.58
1.5. Effectiveness of Antidepressants
1.5.1.  Clinical Trials in Specialized Populations
Although antidepressant medication is the most common form of treatment for 
depression  in  older  adults,  relatively  little  is  known  about  whether  pharmacologic 
treatment  improves  depressive  symptoms  that  do  not  meet  DSM-IV  criteria  for 
depression, dysthymia or minor depression in this population.  As will be discussed, most 
of what we know regarding the effectiveness of antidepressants in older adults comes 
from clinical trials, many of which have included mixed-age samples (i.e., participants < 
65  years  and  ≥65  years),  and  specialized  populations,  such  as  patients  who  are 
institutionalized or being treated by a psychiatrist rather then a primary care provider, 
The results from such trials may not be generalizable to the population of depressed older 
adults who are commonly seen in clinical practice.
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In 1997, a consensus statement was released regarding both pharmacological and 
non-pharmacological treatment of depression in late-life which stressed that there were 
effective  treatments  for  depression  and  that  aggressive  approaches  to  diagnosis  (i.e. 
routine screening followed by diagnostic testing for patients that have elevated depressive 
symptoms)  and  treatment  (i.e.  treatment  for  a  long  duration  and  medication  at 
recommended doses) are warranted.1  In 1999, a subsequent consensus statement  was 
released that drew attention to the relative paucity of mental health care for the geriatric 
population and the need for increased research.59  In preparation for the 2002 consensus 
statement on the treatment  of depression in late-life,  Salzman et  al.  evaluated clinical 
trials of antidepressant treatment in adults, aged 65 years or older.  These investigators 
found that  there  has  been  an  increase  in  the  number  of  clinical  trials  evaluating  the 
efficacy of antidepressants in older adults since 1994.60  Between 1996-2001, 97 studies 
were conducted that evaluated antidepressant treatment in older adults; of these, 60 were 
comparative studies (i.e., efficacy studies) and 37 were trials that were inactive-placebo 
controlled trials.60  These clinical trials generally found antidepressants to be effective, 
defined generally as a reduction in a depression score and/or remission of depression. 
However, the participants in these clinical trials were not representative of the general 
older  adult  population  who  most  commonly  receive  these  medications.  Rather,  the 
participants in these trials had major depression and/or dysthymia, diagnoses that are both 
defined  by  the  DSM-IV;  were  primarily  treated  by  specialists,  such  as  psychiatrists, 
rather  than  primary  care  physicians;  or  represented  specialized  populations  of  older 
adults, such as in-patients, those in nursing homes or those with dementia.60  Because 
these studies primarily evaluated the effect of antidepressant medication on depression 
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that met DSM-IV criteria, the effectiveness of antidepressants on depressive symptoms 
that do not meet the DSM-IV threshold remains unclear. 
A landmark study, the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D),  evaluated  a  system  that  would  optimize  the  delivery  of  antidepressant 
medication to outpatients in both a primary care setting as well as a psychiatric setting.61, 
62  The goals of the study were to demonstrate  that  proper delivery of antidepressant 
medication for depression in the “real-world” can be as nearly as effective as in clinical 
trials.63  STAR*D was conducted in adults >55 years and operationalized remission as a 
score  <5  on  the  Quick  inventory  of  depressive  symptomology-self  rate  score  and 
improvement in mood was also measured by change in the Hamilton Depression Rating 
Scale  HDRS-17  64-66 67  The  study was designed to  evaluate  a  4-tiered  algorithm for 
treating  depression.  Results  from  this  study  showed  that  the  rate  of  remission  was 
approximately 30% in all patients receiving Citalopram, which was the first line therapy. 
If  the patient  did not enter  remission by 14-weeks,  their  medication was switched or 
augmented, subsequently resulting in remission in an additional 30% of the remaining 
subjects.64  Unlike  many  clinical  trials,  this  study  included  adults  with  significant 
comorbid medical and psychiatric problems, thus making the results applicable to a larger 
population.65  One of the salient  findings was that the majority of patients  who were 
treated with an antidepressants for 14-weeks with Citalopram did not have remission of 
their depression.66, 67  By augmenting or changing the antidepressant medications each 14-
week step remission rates were  about 33% after one step, 50% after two steps, 60% after 
three steps, and 70% after four steps.61
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1.5.2. Clinical Trials in Primary Care
There  are  very  few clinical  trials  examining  antidepressant  treatment  in  older 
community-dwelling adults who are treated by their primary care physicians;  yet,  this 
group comprises  the  majority  of  older  adults  who are  prescribed  antidepressants.   A 
systematic review in 2001 by Freudenstein et al.68  identified only seven high quality 
randomized  controlled  studies  that  evaluated  the  effectiveness  of  pharmacologic 
treatment  of  depression  in  a  primary  care  setting  and  included  older  adults  from  a 
general,  non-specialized  population.68  Studies  by  Ekselius  et  al.  and  Patris  et  al. 
compared two antidepressants, Citalopram vs. Sertraline and Citalopram vs. Fluoxetine, 
respectively, in older adults with major depression in the primary care setting.69, 70  Both 
studies  showed a reduction  in the severity of depressive symptoms in each treatment 
group  as  ascertained  by  the  Montgomery-Asberg  Depression  Rating  Scale,  with  no 
difference between the antidepressant agents.69, 70  None of the studies in this systematic 
review  addressed  the  effectiveness  of  antidepressant  treatment  in  older  adults  with 
depressive symptoms not meeting DSM-IV criteria. 
In addition  to the studies  identified  by this  systematic  review,  we identified  a 
randomized controlled trial that evaluated the effectiveness of antidepressant treatment in 
older  adults  without  major  depression  in  a  primary  care  setting.   Participants  were 
classified as depressed if they met DSM-IV criteria for dysthymia or had met modified 
DSM-IV criteria for minor depression, meaning that they were required to have 4 weeks 
of 2 to 3 symptoms rather than 2 weeks of 2 to 4 symptoms usually required for the 
diagnosis. In this randomized controlled trial, participants treated with the antidepressant 
medication  Paroxetine  showed  moderate  improvement  of  dysthymia  and  minor 
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depression,  as  determined  by  comparing  the  mean  reduction  in  the  20-item Hopkins 
Symptom Checklist Scale in the treatment group with those who received placebo.71
A very recent meta-analysis72, which was not restricted to older adults, compared 
the  efficacy  and  acceptability  of  12  major  antidepressants  (bupropion,  citalopram, 
duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, 
reboxetine,  sertraline,  and  venlafaxine)  among  persons  with  major  depression. 
Escitalopram, mirtazapine, sertraline, and venlafaxine were significantly more efficacious 
than the other antidepressants.  Efficacy was defined as a reduction of at least 50% from 
the baseline  score on the Hamilton  depression rating scale  (HDRS) or Montgomery–
Asberg depression rating scale (MADRS), or who scored much improved or very much 
improved  on  the  clinical  global  impression  (CGI)  at  8  weeks.   Among  the  four 
antidepressants that were found to be efficacious, sertraline and escitalopram were the 
best tolerated.
1.5.3. Observational Studies in Primary Care
To  the  best  of  our  knowledge,  no  studies  have  evaluated  the  efficacy  or 
effectiveness of antidepressants in older adults seen in primary care whose depressive 
symptoms  do  not  meet  a  DSM-IV  threshold  for  depression,  dysthymia  or  minor 
depression.   In  the  Personnes  Agees  Quid  (PAQUID)73 study,  a  large  representative 
cohort  of  older  community-dwelling  older  adults  age  > 65  in  southwest  France,  the 
researchers evaluated antidepressant use and depressive symptoms between 1988-1999.73 
Whereas this study found that the prevalence of participants with depressive symptoms 
decreased during the span of the study,  while antidepressant  use increased during the 
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same time period it did not determine whether antidepressants were associated with a 
reduction in depressive symptoms.
In a longitudinal study, Blazer et al. 74 also attempted to determine the association 
between  antidepressant  use  and  depressive  symptoms.   These  investigators  found no 
association between antidepressant use and the overall burden of depressive symptoms. 
However, the study was not designed to determine the effectiveness of antidepressant 
medications, but did show that the CESD Scale scores were not significantly associated 
with antidepressant use. 
The effectiveness of antidepressants in a more natural or “real world setting”  is 
uncertain.  The few available “real world” studies (i.e. studies that recruit participants 
from the community and have more lax inclusion/exclusion criteria)  have shown that 
nearly 80% of older adults who are treated for their  depression by their primary care 
physician fail to improve or relapse back into depression by 6 months to 2 years.75-77
1.6. Questioning the Current Research on Antidepressant Efficacy
Much of the published research on antidepressant efficacy in adults, not limited to those 
age 65 and older, have reported modest benefits.  However, two recent meta-analyses, 
which  have  evaluated  the  efficacy  of  antidepressants  by  combining  published  and 
unpublished  reports,  have  demonstrated  that  the  efficacy  of  antidepressants  is  likely 
overstated  due  to  publication  bias.78  Furthermore,  a  recent  report  by Turner  et  al.78, 
comparing data from the Food and Drug Administration (FDA) to publications related to 
antidepressant drug efficacy, found widespread discrepancies.  Specifically, Turner et al. 
78 identified 74 FDA registered studies that involved tests of antidepressant efficacy. They 
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found that 31% of the studies were not published, involving 3449 study participants.  Of 
the 74 registered FDA studies with positive findings, 37 out of the 38 were published. 
While out of 36 studies with negative findings, 22 were not published, 11 were published 
in a misleading way that made them appear positive, and 3 were published in a way that 
accurately reflected the negative results.   Published studies suggested 94% of studies 
were positive, whereas the FDA records showed that 51% were positive.
In  a  recent  meta-analysis  by  Kirsch  et  al.79,  when  data  from the  FDA  were 
combined  with  those  from  published  reports,  the  drug–placebo  differences  in 
antidepressant efficacy increased as a function of baseline severity, but the benefits were 
relatively small even for most severely depressed patients.79
1.7. Antidepressant Use and Transitions Between Depression States
Because  depression  is  often  a  chronic  condition  with  a  remitting/relapsing 
course,80,  81  preventing the next episode of depression is  important.   A meta-analysis 
identified  studies  that  evaluated  the  prognosis  of  depression  and  elevated  depressive 
symptoms  in  older  adults  (age  >60).   They identified  12 studies  of  the  prognosis  of 
depression in elderly community and primary care populations. The combined results of 
these studies  indicated  that  24  months  after  enrollment,  33%  were well,  33%  were 
depressed, and 21% had died.77  In two years the prognosis of depression is poor in older 
adults.
The  remitting/relapsing  nature  of  depression  may  be  evaluated  by taking  into 
consideration  transitions  between  a  depressed  state  and  not  depressed  state.   Recent 
evidence from the PEP Study has indicated that transitions into and out of depression in 
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older  persons  occur  frequently  over  a  72-month  period,  a  longer  timeframe than  has 
previously been evaluated.82  Of the 269 participants  (35.7%) who were depressed at 
some point during the 72 months of follow-up, 48 (17.8%), 30 (11.2%), 17 (6.3%), and 
12 (4.5%) were depressed during 2, 3, 4, and 5 consecutive time points, respectively.82 
Based on prior analysis of the PEP data not all participants who were depressed remained 
depressed  and some participants  who were  not  depressed transitioned  to  a  depressed 
state.   The  study’s  primary  aim  was  to  determine  if  there  were  gender  differences 
between those who transitioned into or out of depression. A transition from a depressed 
state  to  a  non-depressed  state  may  be  considered  to  be  remission  or  recovery  from 
depression.  Similarly, a transition from a non-depressed state to a depressed state may 
represent relapse.
In the current study, we sought to evaluate the association between treatment with 
antidepressant  medications  and  changes  in  depressive symptoms  over  time  in 
community-dwelling older adults, thereby improving the “real-world” understanding of 




To characterize depression and antidepressant use among older adults over time.
Aim #2A
To test the hypothesis that the use of antidepressant medications is associated with 
a reduction in depressive symptoms in older adults over time.
Aim #2 B
To test the hypothesis that the likelihood of transitioning from a depressed state to 
a non-depressed state will be higher among those taking antidepressant medications as 
compared with those not taking antidepressant medications.   
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3. Methods
3.1. Study Population 
The study sample included the 754 participants of the Precipitating Events Project 
(PEP),  a  prospective  cohort  study of  nondisabled,  community-living  persons  aged 70 
years or older residing in New Haven County.83  Enrollment occurred between March 
1998 and October 1999, and participants were identified though a computerized listing of 
3157 age-eligible members of a large health plan in New Haven, Connecticut. Potential 
participants were mailed a letter that briefly described the study and explained that they 
would be contacted by phone.  During the phone interview, eligibility was assessed, and a 
home visit  was  scheduled among consenting  eligible  persons.  During the home visit, 
eligibility was verified,  informed consent was obtained, and a comprehensive baseline 
assessment was completed.83
PEP  was  designed  to  evaluate  the  effect  of  precipitating  events  (e.g., 
hospitalization) on subsequent disability in older persons.  Members were eligible if they 
were  community-living,  English-speaking,  and  nondisabled  (required  no  personal 
assistance) in four key activities of daily living: bathing, walking across a room, dressing, 
and  transferring from a chair.   Plan members  were excluded based on three  criteria: 
diagnosis of a terminal illness with a life expectancy less than 12 months, plans to move 
out  of  the  New  Haven  area  during  the  next  12  months,  and  significant  cognitive 
impairment with no available proxy.83  The participation rate was 75.2%.  During the 7.5-
year follow-up period between March 1998, and January 2007, 279 participants died after 
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a median of 54 months, and 32 dropped out of the study after a median of 27 months. 
The Human Investigation Committee at Yale University approved the study.
3.2. Data Collection
Face-to-face  in-home  assessments  were  completed  at  baseline  and  every  18 
months for up to 90 months (i.e., up to 6 possible assessments) by highly trained research 
nurses using standard procedures.  Each nurse was thoroughly trained and the interviews 
were guided by the use of an assessment booklet that included all scripts to be read to the 
participant followed by a prompt to the next question. 
During the baseline assessment,  data  were collected on age,  gender,  race,  and 
educational  level.   During  the  baseline  and each  subsequent  face-to-face  assessment, 
medical  comorbidity  was  ascertained  based  on  the  presence  of  nine  self-reported, 
physician-diagnosed chronic conditions,  including hypertension,  myocardial  infarction, 
congestive heart failure, stroke, diabetes, hip fracture, arthritis, chronic lung disease, and 
cancer. Cognitive status was assessed during each assessment using the Folstein Mini-
Mental State Exam (MMSE), with scores ranging from 0 (lowest) to 30 (highest).84  Gait 
speed was assessed by asking the participants to walk back and forth over a 10-foot (3-m) 
course as quickly as possible.  A timed score of greater than 10 seconds on the rapid gait 
test  indicated  that  the  participant  was  physically  frail.85  Deaths  were  identified  and 
confirmed by review of local obituaries and/or an informant. 
3.2.1. Independent Variable: Antidepressant Use 
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Use of antidepressant medications was ascertained directly by a one of the trained 
nurse researchers. Participants were asked to retrieve all of their medications and were 
reminded to check their purse and night table, etc. If a medication was not retrieved, the 
nurse asked to see the participant’s medication list. If a list was unavailable, they were 
asked to recall medications taken in the last two weeks.  The nurse wrote down the name 
of each of the medications on the data collection form and antidepressant medications 
were subsequently coded based on the American Hospital  Formulary system (AHFS) 
code 28.16.04.
In the present study, antidepressants included the use of a Tricyclic antidepressant 
(TCA),  Selective  Serotonin  Reuptake  Inhibitors  (SSRI),  or  Non-SSRI/Non-TCA. 
Trazodone was not considered an antidepressant because it is primarily prescribed as a 
sleep aid.86  Similarly, Amitriptyline was not included as an antidepressant because it is 
most commonly prescribed in older persons as a sleep aid or for pain at lower doses; and 
data were not collected on medication dose or schedule.87-90
3.3. Primary Outcome Variable: Depression Change Score
Depressive  symptoms  were  assessed  during  each  of  the  six  face-to-face 
assessments  (i.e.,  baseline,  and 18, 36, 54, and 72 and 90 months) using the 11-item 
Center for Epidemiological Studies-Depression scale (CESD).42, 43  The CESD asks about 
symptoms that have occurred during the past week, such as “I did not feel like eating; my 
appetite was poor” or “I enjoyed life”. Responses on each of the 11 items were scored 0 = 
rarely  or  never,  1  =  some of  the  time,  or  2  =  much  or  most  of  the  time  and were 
subsequently summed to yield a total depressive symptoms score for each participant. 
Scores were transformed to be compatible with the 20-item CESD91; hence, total scores 
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ranged  from  0  to  60,  with  higher  scores  indicating  more  depressive  symptoms. 
Depressive symptoms data were complete for 100% of the participants at baseline and 
95%, 93%, 91%, 90% and 95% of the non-decedents at 18, 36, 54, 72 and 90 months, 
respectively.
Change in depressive symptoms was determined for each 18-month interval by 
calculating the difference in the CESD Scores between the two relevant time-points (i.e. 
the baseline CESD score was subtracted from the 18-month CESD score.)  A negative 
change  score  indicated  an  improvement  in  symptoms  while  a  positive  change  score 
indicated a worsening of symptoms.
Table 1: CESD Depression Scale
Instruction to Participant:
I would now like to ask you a few questions are about how you have been feeling.  For 
each of the following statements, please tell me how often you have been feeling that 
way during the past week.









1. I felt that everything I did was an 
effort – How often have you been 
feeling this way?
1 2 3 7 8
2. I did not feel like eating; my 
appetite was poor.
1 2 3 7 8
3. My sleep was restless. 1 2 3 7 8
4. I felt depressed. 1 2 3 7 8
5. I was happy. 1 2 3 7 8
6. I felt lonely. 1 2 3 7 8
7. People were unfriendly. 1 2 3 7 8
8. I enjoyed life. 1 2 3 7 8
9. I felt sad. 1 2 3 7 8
10. I felt that people disliked me. 1 2 3 7 8
11. I could not get “going”. 1 2 3 7 8
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3.4. Secondary Outcome Variable: Transitions into and out of Depressed/Not Depressed 
States
Participants with CESD scores  >20 were considered to be depressed.  This cut 
point has previously been shown to enhance the likelihood of detecting subsyndromal 
depression among community-living older persons.92,93  Participants were classified as 
depressed, non-depressed, or dead at each time-point.  Transitions for the purpose of this 
study was defined as passage from one state to another, also including the possibility that 
they remain in the same state.  Participants subsequently could have 6 possible transitions 
from one time-point to the next: 1) depressed to not depressed; 2) depressed to depressed; 
3) depressed to dead; 4) not depressed to depressed; 5) not depressed to not depressed; 6) 
not depressed to dead.  While evaluating the association between antidepressant use and 
death was not a primary aim of the study, this transition needed to be included in order to 
account  for  the  significant  source  of  missing  data.  The  missing  data  in  longitudinal 
epidemiological studies on older adults is often death, and to assume they are missing at 
random would bias the results.
3.5. Statistical Analysis for Univariate and Bivariate Findings
At each time-point, we determined the descriptive statistics f for the demographic 
(age, race, gender and education level) and the clinical  covariates (number of chronic 
conditions,  cognitive  status  score,  physical  frailty  and  depressive  symptoms).   We 
compared participant characteristics (demographic and clinical covariates) between those 
with  and  without  depression,  and  those  who  were  and  were  not  treated  with  an 
antidepressant medication using 2 or t test statistics at each time-point. 
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3.6. Change Score Model
3.6.1. Statistical Analysis for Change Score Model
We compared the depression change score between those who were and were not 
treated with an antidepressant for each 18-month interval using general linear models. 
Intervals refer to two time-points that are combined.  The descriptive data such as age, 
CESD score, MMSE, frailty and number of chronic conditions in each interval was from 
the earlier time-point.  For example, the data in Interval 2 would contain the descriptive 
data  would  be  from  the  18-month  interviews  in  addition  to  the  change  score  and 
transition data that will be described in the following paragraphs. Using intervals, we can 
evaluate the association between antidepressant use at the beginning of each interval and 
subsequent change in depressive symptoms from the beginning to the end of the interval. 
The following figure illustrates how the time-points combined make up the intervals that 
will be discussed.
Figure 1 :Illustration of time-points versus intervals
Three models were run to evaluate the association between antidepressant use and 
change  in  depressive  symptoms.   The  first  model  was  unadjusted,  the  second  was 
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adjusted for demographic features (age, race, gender and education), and the third was 
adjusted for demographic such as: age (continuous), race (white vs. other), educational 
level (continuous variable), and clinical covariates such as: number of chronic conditions 
(continuous variable), frailty (yes vs. no) and cognitive status (continuous score).  
We  evaluated  the  longitudinal  association  between  antidepressant  use  and 
depression  change  score  by  using  a  repeated  measures  linear  mixed  model.   The 
covariance  structure  was  chosen  by  determining  which  model  had  the  best  fit  by 
comparing the Akaike's information criterion (AIC).  The AIC allows us to determine the 
goodness of fit of our estimated statistical model.  The different model structures were 
ranked according to their AIC and the final covariance structure chosen was the Toeplitz 
model since it had the lowest AIC, thus providing the best fit.  
3.7. Transition Models
3.7.1. Statistical Analysis for Transition Models
For each of the 18-month intervals,  we calculated transition rates according to 
whether  (or  not)  participants  were  taking  an  antidepressant  medication  for  the  six 
possible transitions, defined based on the three outcome states: non-depressed, depressed, 
and death.  2 or Fisher exact statistics were used to evaluate the bivariate associations 
between treatment and the six possible transitions for each time interval.  To determine 
whether the observed transitions were clinically meaningful, we calculated the percentage 
of transitions that represented absolute changes in the CESD scores of 1 to 3 (small), 4 to 
9 (moderate), 10 to 19 (large), and 20 or more (very large) points for each time interval.
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We evaluated the association between antidepressant use and the likelihood of the 
6  possible  transitions  over  time  using  longitudinal  methods  that  optimized  statistical 
power.  The first longitudinal model included participants who were not depressed at the 
beginning of any 18-month interval, with participants who were not depressed during the 
entire interval (i.e.,  at 2 consecutive 18-month time points) serving as the comparison 
group.  Specifically, we ran generalized multinomial logit models for nominal outcomes 
that  were  estimated  with  a  generalized  estimating  equation  and  used  exchangeable 
correlation structures.  The second longitudinal model included participants who were 
depressed  at  the  beginning  of  any  18-month  interval,  with  participants  who  were 
depressed during the entire interval serving as the comparison group.
The magnitude of association was determined by odds ratios, which were adjusted 
for  age  (continuous),  race  (white  vs.  other),  educational level  (continuous  variable), 
number  of chronic conditions (continuous variable),  frailty (yes  vs.  no) and cognitive 
status (continuous score).  Prior to running the fully adjusted model, an unadjusted model 
was run and then a semi-adjusted model was run that controlled for demographic features 
alone.
3.8. Sensitivity Analysis
To  ensure  that  our  results  were  robust,  we  performed  two  additional  sets  of 
analyses.  First, to address the possibility that participants who were depressed at baseline 
might differ from those who subsequently developed depression, we re-ran the models 
after  excluding  participants  who were  depressed  at  baseline.   Second, we re-ran  our 
models  after  imputation  for  the  small  amount  of  missing  data  for  the  CESD score, 
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MMSE, number of chronic conditions and frailty, collected during each of the 18 month 
assessments.  Multiple imputation was used with 50 draws per missing observation.  The 
imputations were conducted in a longitudinally sequential fashion.  During imputation, 
decedents were removed after death to ensure that their covariates were only informative 
prior to death.  This sequential  imputation strategy retained the temporal order of the 
longitudinal data and prevented incorrect inference due to potential bias of non-temporal 
associations and effects of retaining descendents in the data imputation.  All covariates 
used in the main model were used to develop the model with the imputed data. In the 
model using the imputed data, a categorical variable for MMSE, rather than a continuous 
variable was used.  Participants with an MMSE score of <=24 were categorized as having 
cognitive impairment.
3.9. Power Calculation
Power calculations were performed using PASS software. For the linear model, 
we  did  a  post-hoc  analysis  and  estimated  power  using  an  inequality  test of  two 
proportions in a repeated measures design. For group sample sizes during interval 1 of 58 
for  those  on an antidepressant  and 679 not  on an antidepressant,  we achieved  100% 
power to detect a difference in the CESD change score of 2.44-points in a design with 5 
repeated  measurements  having  a  Toeplitz  covariance  structure  when  the  standard 
deviation is 0.27.  For the transition model, we achieved 100% power using an inequality 
test  of two proportions in a repeated measure design. Approximately 650 participants 
who have data at a minimum of 2 time-points. The power was estimated to detect an odds 
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ratio of 2.0 thereby denoting at least a 100% increase in the rate of transitioning from 
depressed to non-depressed (or from non-depressed to depressed).
All  statistical  tests  were  2-tailed,  and  P<0.05 was  considered  statistically 
significant. Analyses were performed used using SAS statistical software, version 9.194 




The characteristics of the participants at each time point are provided in Table 1. 
At baseline, the mean age was 78.4 years, and two-thirds of participants were women. 
The average number of chronic conditions increased over time, from 1.75 at baseline to 
2.34 at 90 months.  Similarly, the proportion of frail participants increased from 43% at 
baseline to 56% by 90 months.













Age, yrs.; Mean 
(SD)
78.4 (5.3) 79.6 (5.1) 80.9 (5.1) 82.2 (4.9) 83.7 (4.8) 84.8 (4.7)
Race, Non-white; 
N (%)
72 (9.6) 69 (9.8) 64 (10.0) 58 (10.3) 54 (10.8) 49 (11.1)
Female; N (%) 487 (64.6) 439 (65.0) 405 (66.2) 359 (66.7) 310 (65.8) 281 (67.1)
Education, yrs; 
Mean (SD)
12 (2.9) 12 (2.9) 12 (2.8) 12 (2.9) 12.1 (2.8) 12 (2.8)
No. of chronic 
conditions;a 
Mean (SD)
1.75 (1.2) 1.95 (1.3) 2.06 (1.3) 2.14 (1.3) 2.26 (1.3) 2.34 (1.3)
Cognitive status;b 
Mean (SD)
26.8 (2.5) 26.4 (2.9) 26.3 (3.4) 25.5 (3.9) 25.3 (4.7) 25.2 (4.8)
Frailty; N(%) 322 (42.7) 287 (42.5) 265 (43.3) 265 (49.4) 259 (55.0) 234 (56.1)
Depression;c 
N(%)
100 (13.3) 116 (17.2) 124 (20.3) 109 (20.3) 91 (19.1) 98 (23.4)
a. The 9 self-reported, physician-diagnosed chronic conditions included hypertension, myocardial 
infarction, congestive heart failure, stroke, diabetes mellitus, hip fracture, arthritis, chronic lung 
disease, and cancer (other than minor skin cancer).
b. As assessed by the Mini-Mental State Examination (MMSE).
c. CESD score >20
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4.2. Participants with Depressive Symptoms
A total of 100 participants (13.3%) were depressed (i.e., had a CESD score of 
>20) at baseline.  The proportion of participants who were depressed increased over time, 
such that at 90-months 23% of participants were depressed.  As indicated in Table 2, the 
mean age and the proportion of non-white participants were similar for those with and 
without depression at all time points.  Participants with depression were more likely to be 
women,  have  less  education  and  report  a  higher  number  of  chronic  conditions. 
Depressed participants were also nearly twice as likely to be frail as compared with non-
depressed participants.  Cognitive status was lower among depressed participants at each 
time point, with the exception of the 54-month time-point.  
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Age, y 78.6(5.4) 78.4(5.2) 0.79 80.4(5.42) 79.5 (5.0) 0.10 81.6(5.3) 80.7 (5.0) 0.09
Female Sexb 86 (86.0) 401(61.3) <.001 99 (85.3) 340(60.8) <.001 102(82.3) 303(62.1) <.001
Race, non-
whiteb
14 (14.0) 58 (8.9) 0.10 10 (8.6) 56 (10.0) 0.65 14 (11.3) 48 (9.8) 0.63




2.08(1.4) 1.7 (1.2) 0.004 2.2 (1.32) 1.9 (1.2) 0.039 2.4 (1.4) 2.0 (1.2) <.001
Cognitive 
status
26.0(2.8) 26.9 (2.4) 0.002 25.4 (3.2) 26.6 (2.8) <.001 25.4 (3.5) 26.5 (3.3) 0.002
Frailty 62 (62.0) 260(39.8) <.001 72 (62.1) 215(38.5) <.001 84 (67.7) 181(37.1) <.001




























Age, y 82.7 
(4.9)
82.0 (4.9) 0.19 84.3 (5.1) 83.6 (4.7) 0.19 85.3 (4.9) 84.7 (4.6) 0.25
Female Sexb 96 (88.1) 263(61.3) <.001 74 (81.3) 236(62.1) <.001 77 (78.6) 204(63.6) <.001
Race,  non-
whiteb
13 (11.9) 42 (9.8) 0.52 8 (8.8) 40 (10.5) 0.62 10 (10.2) 38 (11.9) 0.64
Education 11.1 
(2.8)









25.6 (3.8) 0.12 23.6 (5.6) 25.7 (4.3) <.001 23.3 (6.0) 25.8 (4.3) <.001
Frailty 76 (69.7) 189(44.1) <.001 65 (71.4) 194(51.1) <.001 72 (73.5) 162(50.5) <.001
CESD 26.1(5.9) 7.3 (6.1) *** 25.2(5.75) 8.4 (6.2) *** 26.3 (6.3) 8.2 (6.0) ***




As shown in Figure 1,  at  any given  time-point,  approximately 10-15% of  the 
study population was taking an antidepressant medication.  The proportion of participants 
taking an antidepressant increased at each successive time-point, with the exception of 90 
months where the rate approximated that of at 54-months.  
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Table 3 presents the breakdown of categories of antidepressants reported by the 
study  participants  at  each  time-point.   At  baseline,  there  were  40(69%)  out  of  58 
antidepressant  medications  were  for  SSRI’s  the  remaining  antidepressant  medications 
were TCA’s or Non-SSRI/Non-TCA antidepressants. At 90-months, 48 (72.2%) of the 66 
antidepressant medications were SSRI’s and 14(21.2%) of the antidepressant medications 
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were non-SSRI/non-TCA antidepressant medication. The decline in TCA antidepressant 
medications from baseline to 90-months was 19.8%.
Table 3: Antidepressant Medications Ascertained at Each Time-Pointa














Desipramine 2 (3.4) 2 (2.8) 0 (0) 0 (0) 0 (0) 0 (0)
Doxepin 1 (1.7) 0 (0) 1 (1.2) 0 (0) 0 (0) 1 (1.5)
Imipramine 2 (3.4) 3 (4.2) 4 (4.9) 2 (2.3) 2 (2.4) 2 (3.0)
Nortriptyline 10 (17.0) 6 (8.5) 5 (6.1) 3 (3.4) 2 (2.4) 1 (1.5)
TCA %Total 15 (25.9) 11 (15.5) 10 (12.2) 5 (5.7) 4 (4.8) 4 (6.1)
SSRI’s
Citalopram 1 (1.7) 5 (7.0) 13 (15.9) 14 (15.9) 9 (10.8) 10 (15.2)
Escitalopram 0 (0) 0 (0) 0 (0) 3 (3.4) 14 (16.9) 10 (15.2)
Fluoxetine 8 (13.6) 12 (16.9) 10 (12.2) 11 (12.5) 7 (8.4) 4 (6.1)
Paroxetine 14 (23.7) 10 (14.1) 15 (18.3) 12 (13.6) 9 (10.8) 9 (13.6)
Sertraline 14 (23.7) 25 (35.2) 22 (26.8) 20 (22.7) 21 (25.3) 15 (22.7)
Serzone 3 (5.1) 1 (1.4) 0 (0) 1 (1.1) 0 (0) 0 (0)
SSRI %Total 40 (69.0) 53 (74.6) 60 (73.1) 61 (69.3) 60 (72.3) 48 (72.7)
Non-SSRI/Non-TCA
Bupropion 0 (0) 3 (4.2) 2 (2.4) 9 (10.2) 7 (8.4) 4 (6.1)
Duloxetine 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.2) 1 (1.5)
Mirtazapine 0 (0) 2 (2.8) 6 (7.3) 7 (8.0) 6 (7.2) 4 (6.1)
Venlafaxine 3 (5.2) 2 (2.8) 4 (4.9) 6 (6.8) 5 (6.0) 5 (7.6)
Non-SSRI/Non-TCA 
%Total
3 (5.2) 7 (9.9) 12 (14.6) 22 (25.0) 19 (22.9) 14 (21.2)
N= Reflects number of antidepressants and not number of participants because some participants 
could be taking more than 1 antidepressant.
Table 4 presents the characteristics  of the study population at  each time point 
according to antidepressant  use.   Age,  race and education did not differ  significantly 
between those taking and not taking an antidepressant at any time point.  Women were 
more likely to be taking an antidepressant than men (p<0.05), although there was not a 
significant  gender  difference  at  72  or  90  months.   At  54-months  and  72-months, 
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participants  taking  an  antidepressant  were  more  likely  to  have  a  greater  number  of 
chronic conditions than those not taking an antidepressant.  At each time point, with the 
exception  of  baseline,  participants  taking an  antidepressant  were more  likely to  have 
lower cognitive scores as assessed by the MMSE (p<0.05).  At most time-points except at 
baseline and 18-months, participants taking an antidepressant were more likely to be frail 
than  those  not  taking  an  antidepressant  (p<0.05).   In  addition,  those  taking 
antidepressants  had  a  higher  depressive  symptoms  score  than  those  not  taking  an 
antidepressant (p<0.05).
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Age, y 77.8(5.3) 78.5(5.3) 0.26 79.3(4.9) 79.7(5.1) 0.36 80.7(5.4) 80.9(5.0) 0.51
Female Sex 56 (74.7) 431(63.5) 0.03 62 (76.5) 377(63.5) 0.03 59 (73.8) 346(65.0) 0.03
Race,non-
white
4 (6.9) 68 (9.8) 0.47 6 (8.8) 63 (9.8) 0.79 4 (5.3) 60 (10.6) 0.14
Education 12.0(2.5) 12.0 (2.9) 0.67 11.8(2.8) 12.0 (2.9) 0.30 12.0(2.7) 12.0 (2.9) 0.35
No.of  chronic 
conditions
1.92(1.2) 1.73 (1.2) 0.29 2.04(1.3) 1.93 (1.2) 0.55 2.06(1.3) 2.03 (1.3) 0.16
Cognitive 
status
26.7(2.3) 26.8 (2.5) 0.71 25.7(3.7) 26.5 (2.8) 0.03 25.8(4.5) 26.3 (3.2) 0.03
Frailty 27 (46.6) 295(43.4) 0.54 35 (51.5) 258(43.4) 0.14 49 (64.5) 230(43.2) <.001
Depressionc 17 (29.3) 83(12.2) <.001 27 (39.7) 89 (15.0) <.001 24 (31.6) 100(18.8) 0.001


























Age, y 82.4(4.9) 82.1 (4.9) 0.90 84.0 (5.0) 83.7 (4.7) 0.60 84.8(4.7) 84.8 (4.6) 0.49
Female Sex 65 (77.4) 294(64.8) 0.01 63 (77.8) 247(63.3) 0.08 47 (70.1) 234(66.5) 0.68
Race,non-
white
7 (8.9) 51 (10.5) 0.65 6 (7.6) 48 (11.4) 0.32 7 (11.1) 42 (11.2) 0.98
Education 11.6(2.8) 12.1 (2.9) 0.12 11.9 (2.6) 12.1 (2.8) 0.69 12.0(2.7) 12.0 (2.9) 0.73
No.of  chronic 
conditions
2.1 (1.3) 2.1 (1.3) 0.02 2.59 (1.4) 2.19 (1.2) 0.01 2.5 (1.3) 2.3 (1.3) 0.46
Cognitive 
status
24.3(5.4) 25.7 (3.5) 0.01 23.5 (6.4) 25.6 (4.2) 0.002 24.1(5.8) 25.4 (4.6) 0.03
Frailty 52 (65.8) 231(50.9) 0.004 57 (72.2) 221(56.7) 0.002 42 (66.7) 210(59.7) 0.11
Depressionc 35 (44.3) 74 (16.3) <.001 29 (36.7) 62 (15.9) <.001 22 (34.9) 76 (21.6) 0.005
CESD 17.6(10.5) 10.1 (9.1) <.001 16.6(10.1) 10.7 (8.5) <.001 16.8(10.9) 11.7 (9.5) <.001
a. See list of medications that qualified as antidepressants in Table 3.
b. Participants with a CESD score > 20.
c. Rate reported.
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Of the 100 participants with depression (i.e.,  CESD>20) at baseline, 17 (17%) 
were  taking  an  antidepressant.   Between  17-31% of  the  depressed  participants  were 
taking an antidepressant during the 90-month time period, as illustrated in Figure 2.
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4.4. Depression Change Score at Each Interval
Table 5 presents the association between antidepressant use and the change in 
depressive symptoms at each interval.  In the unadjusted model, antidepressant use was 
not associated with a change in the CESD score, with the exception of interval 2 where 
antidepressant use was associated with an improvement in CESD score.  These results did 
not change after adjusting for the demographic features.  However, after adjusting for the 
demographic and clinical covariates, antidepressant use was associated with worsening of 
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depressive  symptoms  for  each  interval  except  interval  2.   These  associations  were 
statistically significant for intervals 1, 3 and 5.
Table 5: Association Between Antidepressant Use and Change in Depressive Symptoms 
at Each Interval.
Estimate (ß) Standard error P-value
Unadjusted
Interval 1 0.16 1.08 0.88
Interval 2 -4.69 1.04 <0.001
Interval 3 0.86 1.18 0.47
Interval 4 -2.08 1.08 0.05
Interval 5 0.86 0.86 0.43
Adjusted for demographicsa
Interval 1 0.16 1.08 0.88
Interval 2 -4.71 1.05 <0.001
Interval 3 0.84 1.19 0.48
Interval 4 -2.01 1.08 0.07
Interval 5 0.75 1.08 0.49
Adjusted for demographicsa and clinical covariatesb
Interval 1 2.3 1.1 0.03
Interval 2 -1.3 0.99 0.19
Interval 3 2.7 1.1 0.02
Interval 4 1.1 1.0 0.29
Interval 5 2.5 1.0 0.01
Note: The Parameter estimate (i.e. ß) indicates the magnitude of change in depressive 
symptoms,  with a  positive number indicating worsening of  symptoms and a negative 
number indicating an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic conditions, MMSE score, frailty (y/n) and CESD 
score at the beginning of each interval
4.5. Change Score/Mixed-effects Linear Longitudinal Regression
Table  6  presents  the  results  from  the  final  model  evaluating  the  association 
between  antidepressant  use  and change in  depressive  symptoms  over  time.   Overall, 
antidepressant  use  was  associated  with  an  increase  in  depressive  symptoms  (i.e.  the 
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change  in  the  CESD  score  worsened,  on  average,  by  2.22  points).   However,  this 
association was not statistically significant.
Table  6:  The  Longitudinal  Association  Between  Antidepressant  Use  and  Change  in 
Depressive Symptoms by Mixed-Effects Linear Longitudinal Regression.
Fixed effects Estimate (ß) Standard error P-value
Antidepressant use (yes) 2.22 0.99 0.14
Age (years) 0.01 0.02 0.81
Gender (female) 0.39 0.19 0.04
Education (years) -0.06 0.04 0.08
Race (white) 0.57 0.29 0.05
CESD at beginning of each interval -0.15 0.01 <0.001
Number of chronic conditions 0.34 0.07 <0.001
Frailty (yes) 0.04 0.25 0.88
MMSE (continuous score) -0.13 0.04 <0.001
-2 Log-likelihood 17392.6
Akaike Information Criterion (AIC) 17402.6
ß: linear longitudinal regression coefficient, fixed effect: reflects the mean of the overall 
criteria
P-value for the intercept is a solution from the fixed effects; all other p-values are from 
the type 3 tests of fixed effects.
4.6. Transitions Rates at Each Interval
Table  7A  presents  transition  rates  not  adjusted  for  covariates,  according  to 
antidepressant use, for persons who transitioned from a depressed state to either a non-
depressed state or remained depressed.  At each time point, there was not a significant 
association between antidepressant use and transitioning from a depressed state to a non-
depressed state.  Antidepressant use also was not associated with depressed participants 
remaining depressed.
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Table 7A: Transition Rates Between the Three Outcome States Over Time According to Antidepressant Use.

































N (%) 4 (25.0) 27 (36) 11(44) 30(35.7) 6 (26.1) 42(43.8) 10(30.3) 27(38.6) 10(35.7) 17(27.9)
p-value 0.46 0.50 0.12 0.42 0.49
To Depressed
N (%) 12(75.0) 40(53.3) 12(48) 42(50.0) 13(56.5) 42(43.8) 17(51.5) 35(50.0) 16(57.1) 37(60.7)
p-value 0.09 0.80 0.28 0.90 0.68
To Death
N (%) 0 (0) 8 (10.7) 2 (8.0) 12(14.3) 4 (17.4) 12(12.5) 6 (18.2) 8 (11.4) 2 ( 7.1) 7 (11.5)
p-value 0.18 0.40 0.54 0.36 0.51
As  shown  in  Figure  3A,  most  transitions  from  a  depressed  state  to  a  non-
depressed state were based on moderate to large absolute changes in the CESD score (ie, 
>10); small changes in the range of 1 to 3 points were observed for no more than 30% of 


























Figure 3A: The Absolute Change in CESD Scores For Participants that Transitioned from a 
Depressed State to a Non-depressed State.
+D/-M: Those initially depressed and not taking an antidepressant medication
+D/+M: Those initially depressed and taking and antidepressant medication
The key refers to the absolute change in the CESD.
Table  7B  presents  transition  rates  not  adjusted  for  covariates,  according  to 
antidepressant use, for  persons who transitioned from a non-depressed state to either a 
depressed state or remained non-depressed.  Among the non-depressed, antidepressant 
use was associated with a higher likelihood of remaining non-depressed at each interval, 
with the exception of interval 2.  Participants who were initially not depressed and on an 
antidepressant were more likely to transition to a depressed state for 2 of the 5 intervals. 
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Table 7B: Transition Rates Between the Three Outcome States Over Time According to Antidepressant Use
Interval 1 Interval 2 Interval 3 Interval 4 Interval 5
Antidepressant Use Antidepressant Use Antidepressant Use Antidepressant Use Antidepressant Use
Transitions Yes No Yes No Yes No Yes No Yes No






















p-value 0.04 0.51 0.01 <0.001 0.001
To Depressed
N (%) 7 (18.4) 57 (9.6) 3 (8.6) 64 (12.6) 10(22.2
)
41 (9.6) 9 (15.5) 29 (6.5) 8 (21.1) 32 (9.7)
p-value 0.10 0.36 0.01 0.002 0.06
To Death
N (%) 3 (7.9) 35 (5.9) 2 (5.7) 30 (5.9) 7 (15.6) 37 (8.7) 9 (15.5) 31 (6.9) 6 (15.8) 30 (9.1)
p-value 0.67 0.84 0.11 0.003 0.26
As  shown  in  Figure  3B,  most  transitions  from  a  non-depressed  state  to  a 
depressed state were based on moderate to large absolute changes in the CESD score (ie, 
>10); small changes in the range of 1 to 3 points were observed for no more than 50% of 


























Figure 3B: The Absolute Change in CESD Scores For Participants that Transitioned from a Non-
depressed State to a Depressed State.
ND/-M: Those initially not depressed and not taking an antidepressant medication
ND/+M: Those initially not depressed and taking and antidepressant medication
The key refers to the absolute change in the CESD.
4.7. Generalized Estimating Equations Models
Table 8 presents the unadjusted and adjusted odds ratios from the longitudinal 
models  evaluating  the  association  between  antidepressant  use  and  the  likelihood  of 
transitioning between the three outcome states, among those who were depressed at the 
beginning of each interval.  Antidepressant use was not associated with a transition from 
a depressed state to a non-depressed state over time, meaning that participants taking an 
antidepressant were no more likely to transition to a non-depressed state than they were 
to remain depressed, even after adjusting for demographics and the clinical covariates.
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Table 8: Association Between Antidepressant Use and Transitions Over the Course of 7.5 
Years in Initially Depressed Participants.
Odds Ratio 95% CI
Unadjusted
Depressed 1 --




Not Depressed 0.80 0.5-1.3
Dead 0.90 0.4-2.0
Adjusted for demographicsa and clinical covariatesb
Depressed 1 --
Not Depressed 0.85 0.5-1.4
Dead 0.49 0.2-1.2
Note: The Parameter estimate indicates the magnitude of change in depressive symptoms 
and a positive number indicates worsening of symptoms, while a negative number indicates 
an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic conditions, MMSE score,  frailty (y/n) and CESD 
score at the beginning of each interval
Table 9 presents the unadjusted and adjusted odds ratios from the longitudinal 
models  evaluating  the  association  between  antidepressant  use  and  the  likelihood  of 
transitioning between the three outcome states, among those who were non-depressed at 
the beginning of each interval.  Results from the unadjusted model indicate that those 
taking  an  antidepressant  were  more  likely  to  transition  from  a  non-depressed  to  a 
depressed state, than to remain non-depressed (OR 2.01, 95% CI 1.3-3.0).  This finding 
persisted  after  adjustment  for  demographic  (OR  1.9,  95%  CI  1.2-2.9)  and  clinical 
covariates (OR 1.79, 95% CI 1.2-2.8).
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Table 9: Association Between Antidepressant Use and Transitions Over the Course of 
7.5 Years in Initially Non-depressed Participants.
Odds Ratio 95% CI
Unadjusted




Not Depressed 1 --
Depressed 1.90 1.2-2.9
Dead 2.46 1.5-4.0
Adjusted for demographics and clinical covariates
Not Depressed 1 --
Depressed 1.79 1.2-2.8
Dead 1.80 1.1-3.0
Note:  The  Parameter  estimate  indicates  the  magnitude  of  change  in  depressive 
symptoms and a positive number indicates  worsening of  symptoms,  while  a negative 
number indicates an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD 
score at the beginning of each interval
4.8. Sensitivity Analysis
4.8.1. Eliminating Participants Who Were Depressed at Baseline
Table 10 indicates that when participants with elevated depressive symptoms at 
baseline were omitted from the analysis, use of an antidepressant medication was still not 
associated with a change in depression scores.
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Table 10 :  The Longitudinal  Association Between Antidepressant Use and Change in 
Depressive  Symptoms  by  Mixed-Effects  Linear  Longitudinal  Regression,  Excluding 
Participants Who Were Depressed at Baseline.
Fixed effects Estimate (ß) Standard error P-value
Antidepressant use (yes) 1.30 1.06 0.21
Age (years) 0.0006 0.02 0.98
Gender (female) 0.35 0.19 0.08
Education (years) -0.06 0.04 0.12
Race (white) 0.44 0.32 0.17
CESD at beginning of each interval -0.16 0.01 <0.001
Number of chronic conditions 0.34 0.08 <0.001
Frailty (yes) 0.05 0.27 0.87
MMSE (continuous score) -0.13 0.04 0.002
-2 Log-likelihood 15210.7
Akaike Information Criterion (AIC) 15220.7
ß: linear longitudinal regression coefficient, fixed effect: reflects the mean of the overall 
criteria
P-value for the intercept is a solution from the fixed effects; all other p-values are from 
the type 3 tests of fixed effects.
As shown in Table 11, for participants who started an interval in a depressed state, 
antidepressant  use  was  not  associated  with  the  transition  from depression  to  a  non-
depressed state.  These findings persisted after adjusting for demographic and clinical 
covariates.  
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Table  11:  Association  Between  Antidepressant  Use  and  Change  in  Depressive 
Symptoms at  Each Interval, in  Initially  Depressed Participants; Omitting Participants 
Who Were Depressed at Baseline.
Odds Ratio 95% CI
Unadjusted
Depressed 1 --




Not Depressed 0.84 0.4-1.7
Dead 0.87 0.3-3.0
Adjusted for demographics and clinical covariates
Depressed 1 --
Not Depressed 0.57 0.4-1.7
Dead 0.49 0.1-1.9
The results are from 4 intervals since we eliminated participants who had depression at 
baseline
Note:  The  Parameter  estimate  indicates  the  magnitude  of  change  in  depressive 
symptoms and a positive number indicates  worsening of  symptoms,  while  a negative 
number indicates an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD 
score at the beginning of each interval
Table 12 provides the results of the generalized estimating equation (GEE) model 
evaluating participants who were not depressed at baseline.  Similar to the GEE results 
from  the  original  models,  participants  taking  an  antidepressant  were  more  likely  to 
transition  from  a  non-depressed  state  to  a  depressed  state  rather  than  to  stay  non-
depressed.  This finding persisted after adjustment for the demographic and the clinical 
covariates (OR=2.43, 95% CI 1.3-4.5).
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Table  12:  Association  Between  Antidepressant  Use  and  Change  in  Depressive 
Symptoms  at  Each  Interval, in  Initially  Not  Depressed  Participants; Omitting 
Participants Who Were Depressed at Baseline.
Odds Ratio 95% CI
Unadjusted




Not Depressed 1 --
Depressed 2.51 1.4-4.5
Dead 2.96 1.6-5.4
Adjusted for demographics and clinical covariates
Not Depressed 1 --
Depressed 2.43 1.3-4.5
Dead 2.19 1.1-4.3
Note:  The  Parameter  estimate  indicates  the  magnitude  of  change  in  depressive 
symptoms and a positive number indicates  worsening of  symptoms,  while  a negative 
number indicates an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD 
score at the beginning of each interval
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4.8.2. Imputed Data
The results did not change appreciably after imputation for missing data.  Using 
imputed  data  for  the  CESD  at  the  beginning  of  each  interval,  number  of  chronic 
conditions, frailty and cognitive status as shown in Table 13, antidepressant use was not 
associated with change in depressive symptoms over time (ß=2.44; SE 0.91; p=0.08).
Table  13:  The  Longitudinal  Association  Between  Antidepressant  Use  and  Change  in 
Depressive Symptoms by Mixed-Effects Linear Longitudinal Regression, Imputed Data 
Results.
Fixed effects Estimate (ß) Standard error P-value
Antidepressant use (yes) 2.44 0.91 0.08
Age (years) -0.07 0.02 0.73
Gender (female) 0.23 0.18 0.22
Education (years) -0.07 0.03 0.04
Race (white) 0.59 0.28 0.04
CESD at beginning of each interval* -0.15 0.01 <0.001
Number of chronic conditions* 0.29 0.07 <0.001
Frailty (yes)* 0.43 0.22 0.04
MMSE (no cognitive deficit)* 0.85 0.30 0.004
-2 Log-likelihood 18435.7
Akaike Information Criterion (AIC) 18445.7
ß: linear longitudinal regression coefficient, fixed effect: reflects the mean of the overall 
criteria
P-value for the intercept is a solution from the fixed effects; all other p-values are from 
the type 3 tests of fixed effects.
*imputed variables
Similarly,  antidepressant  use  was  not  associated  with  a  transition  from  a 
depressed state to a non-depressed state, over time, among those participants who were 
depressed  at  the  beginning  of  each  interval  (Table  14);  but  as  shown  in  Table  15 
antidepressant  use  was  associated  with  a  transition  from  a  non-depressed  state  to  a 
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depressed  state,  over  time,  among  those  participants  who  were  non-depressed  at  the 
beginning of each interval (OR 1.80, 95% CI 1.2-2.8).  
Table 14: Association Between Antidepressant Use and Change in Depressive Symptoms at Each 
Interval, in Initially Depressed Participants, Imputed Data Results.
Odds Ratio 95% CI
Unadjusted
Depressed 1 --




Not Depressed 0.82 0.5-1.3
Dead 0.93 0.4-1.4
Adjusted for demographics and clinical covariates
Depressed 1 --
Not Depressed 0.79 0.5-1.2
Dead 0.70 0.3-1.6
Note: The Parameter estimate indicates the magnitude of change in depressive symptoms and a 
positive  number  indicates  worsening  of  symptoms,  while  a  negative  number  indicates  an 
improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD score at 
the beginning of each interval
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Table 15: Association Between Antidepressant Use and Change in Depressive Symptoms at Each 
Interval, in Initially Not Depressed Participants, Imputed Data Results.
Odds Ratio 95% CI
Unadjusted




Not Depressed 1 --
Depressed 1.88 1.2-2.9
Dead 2.33 1.4-3.8
Adjusted for demographics and clinical covariates
Not Depressed 1 --
Depressed 1.80 1.2-2.8
Dead 1.93 1.2-3.1
Note: The Parameter estimate indicates the magnitude of change in depressive symptoms and a 
positive  number  indicates  worsening  of  symptoms,  while  a  negative  number  indicates  an 
improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD score at 
the beginning of each interval
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5. Discussion
The treatment of depression and depressive symptoms in the older adult consists 
almost  entirely  of  antidepressant  medications  prescribed  in  primary  care  settings. 
However,  there  is  relatively  little  information  on  the  efficacy  or  effectiveness  of 
antidepressant medications on depressive symptoms in the community.  Therefore, this 
longitudinal study of older adults in New Haven county sought to describe the use of 
antidepressant medications over time, to evaluate the association between antidepressant 
use and reduction in the severity of depressive symptoms over time, and to determine if 
antidepressant  use was associated with transitioning from a depressed state  to a non-
depressed  state.   We  found  that  most  participants  with  depression  were  not  taking 
antidepressant medications.  Furthermore, antidepressant use was not associated with a 
reduction in the severity of depressive symptoms over time; nor was it associated with 
transitioning from a depressed state to a non-depressed state.
5.1. Potential Underdiagnosis and/or Undertreatment of Depression
During the 90-month follow-up, between 13% to 23% of the study participants 
had elevated depressive symptoms.  These prevalence rates are slightly higher than the 
rates of 6% to 18% that have previously been reported in the literature.2-6  Reasons for 
this may include the higher mean age and more diverse racial composition of our sample 
compared with the samples in these other studies.95  Furthermore, the PEP study over-
sampled  participants  who  were  physically  frail.  As  prior  studies  have  indicated  that 
frailty  is  associated  with  depression,  the  higher  prevalence  of  frailty  in  our  study 
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population,  as compared with other populations of community-dwelling older persons, 
may account for the higher rates of elevated depressive symptoms reported in our study.17, 
96
5.2. Potential Undertreatment
At all time-points during the 90-month follow-up, more than 60% of participants 
with elevated depressive symptoms were not taking an antidepressant.  Prior studies have 
indicated that depression in older adults is undertreated, such that, at most, no more than 
a third to half of patients who have been identified as depressed are treated by a physician 
by  either/or  pharmacological  or  non-pharmacological  methods..30,  47,  48,97-99  Studies 
evaluating antidepressant use in older adults with depression have reported rates ranging 
from 19% to 42%.97-99  However, what we know about rates of antidepressant medication 
treatment  primarily  comes  from  studies  of  older  adults  with  a  clinical  diagnosis  of 
depression.   In  addition,  with  the  exception  of  one  study,100 the  published  studies 
evaluating  antidepressant  use  in  older  persons  have  been  cross-sectional.97-99  For 
example,  Skoog  et  al.  evaluated  antidepressant  medication  treatment  before  the 
widespread use of SSRI’s and found that 19% of older adults with depressive disorders 
and  24%  of  those  with  major  depression  were  taking  antidepressant  medications.97 
Consequently, relatively little in known about the rates of antidepressant use in depressed 
older persons over time.
In the Longitudinal Aging Study Amsterdam (LASA)101, antidepressant use was 
examined  over  10  years,  from  1992  to  2002,  in  a  representative,  community-based 
population of persons aged 55-85 years.  The rate of antidepressant use ranged from 2% 
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to 5.3%.  As in our study, antidepressant use increased over time in the population as a 
whole, and in the subgroups who had a depressive disorder.  For example, the rate of 
antidepressant use increased from 2.9% to 12.1% among participants who had elevated 
depressive symptoms, defined as CESD >16, and from 15% to 30.4% among those who 
were clinically depressed.
Our study differs from the LASA study in a several ways.  First, our study was 
conducted between 1998-2007, a period during which SSRI’s were first-line therapy for 
depression.  This is important because the rates of antidepressant use have increased since 
the introduction of SSRI’s.  Second, the LASA study population, which included only 
Dutch  participants  living  in  the  Netherlands,  was  much  more  homogeneous  than  our 
population .  Thus, the results may not generally applicable to a population in the United 
States.  Third,  the LASA study interviewed participants every 3 years  for 12 years  (4 
time-points) , while we interviewed participants every 18 months for 7 ½ years (6 total 
time-points).  At 90 months, however, there was a slight decline such that less than 25% 
of participants  with elevated depressive symptoms were taking an antidepressant  (see 
Figure 2 in results).  Because we only have one time-point that demonstrates a decline in 
the rates of antidepressant use, it is difficult to infer the cause.  However, this finding 
raises the question as to whether under treatment and under recognition of depression 
may occur more frequently in the old-old as compared with the young-old.  
Depressive symptoms may go untreated because they are not recognized. Major 
depression  goes  unrecognized  or  underdiagnosed  in  approximately  60% of  the  older 
patients  seen  in  primary  care  settings.102,  103  In  all  adults  major  depression  was 
unrecognized in 44% of patients, those with symptoms that were less severe were more 
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likely to have unrecognized depression.104  While in the old-old (age>85) depression was 
unrecognized  in  75% of  the  patients  by a  primary  care  physician.105  In  hospitalized 
geriatric patients, psychogeriatricians were able to identify 43% of cases of depression 
while the geriatricians only identified 19% of the cases.106  Depression and depressive 
symptoms are missed in more then half of patient’s in a variety of settings.  Physicians 
may  be  better  able  to  identify  patients  with  greater  degrees  of  depression,  thus  not 
identifying the majority of patients  with elevated depressive symptoms who still  may 
benefit from treatment.107-109  While undertreatment of depression may be attributable to 
underrecognition of depression, we could not address this issue directly in the current 
study since we did not have access to medical records.  Nonetheless, increased detection 
of  depressive  symptoms  would  likely  lead  to  enhanced  treatment  of  this  disabling 
disorder, with potential benefits in quality of life and other health outcomes.
There have been some initiatives to increase screening of depressive symptoms in 
older adults  by primary care  physicians.   In one study,  primary care physicians  were 
provided  with information  about  diagnosing  and treating  depression in  older  adults.75 
Despite the increased detection and awareness of depression, this intervention did not 
lead to significant improvement of the patients.75
Overall,  our  findings  highlight  potential  opportunities  to  enhance  the 
identification of depression and to optimize medical treatment of depression among older 
adults.
5.3. Effectiveness of Antidepressants
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Contrary to our hypothesis, we found that antidepressant use was not associated 
with a reduction in the severity of depressive symptoms.  In fact, on average, depressive 
symptoms  worsened  among  participants  taking  antidepressant  medications.   The 
consistency  of  our  findings  over  4  of  the  5  different  time  intervals  provides  strong 
evidence that antidepressant use, as prescribed in clinical practice, is not associated with 
an improvement in depressive symptoms.
As  noted  in  the  Introduction,  what  we  know  about  the  effectiveness  of 
antidepressant medications in older persons primarily comes from clinical trials that have 
included specialized populations such as those being treated in an in-patient setting, those 
being  treated  by  a  psychiatrist,  or  those  who  have  been  diagnosed  with  a  clinical 
depressive disorder.   Consequently,  treatment  recommendations  are extrapolated  from 
findings  that  may  not  be  generalizable  to  the  majority  of  older  adults  who  have 
depressive symptoms .
We  also  evaluated  transitions  into  and  out  of  depression  states  at  18-month 
intervals for 7 1/2 . years, using longitudinal methods that enhanced our power to detect 
clinically meaningful differences.  We found that antidepressant use was not associated 
with the transition from a depressed state to a non-depressed state.  It has been estimated 
that only 40 to 65% of all adults, including older adults, have a favorable response to any 
given antidepressant.110  In 4 out of the 5 time intervals, we found that less than 40% of 
the participants who were depressed and taking an antidepressant medication transitioned 
to a non-depressed state.  In contrast, we found that non-depressed persons who were 
taking an antidepressant were more likely to transition to a depressed state. 
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There are several  possible  reasons why depressive symptoms did not improve 
despite treatment with an antidepressant. First, possible lack of adherence to the medical 
treatment is possible.  Second, the dose of the antidepressant medications may have been 
too  low.   Third,  the  treatment  duration  may  not  have  been  long  enough.  Fourth, 
physicians may have prescribed antidepressant medication to patient’s who were sicker.
It is possible that we found a worsening of depressive symptoms because there 
could  have  been  a  high  degree  of  non-adherence.111  Some  variables  that  have  been 
identified as being related to poor adherence include poorer social support112, less non-
family interaction,  greater basic and instrumental  activities  of daily living limitations, 
poor self-rated health, higher baseline depression scores.113  Of older persons who receive 
a prescription for an antidepressant, less than half fill the prescription.29  Given the high 
prevalence of non-adherence, it is important to have a follow-up period within a couple 
of weeks to determine if the patient started the medication and if they are tolerating the 
medication.29, 36
It is also possible that primary care physicians did not achieve a therapeutic dose 
of the antidepressant medication. In a survey of primary care physicians in Ontario, 
Canada it was found many physicians were not willing to titrate the dose of their 
prescribed antidepressant medications beyond the lower half of the therapeutic range 
even when patients were tolerating the medications without side effects but were not 
responding to treatment.114, 115 Another study found that only 56% of study participants 
were on an adequate dose of antidepressants.115
It  is  possible  the treatment  was sub-optimal  in  duration.   Our 18-month  time-
period would have allowed enough time for the antidepressant to take effect; however 
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participants  may  not  have  been  taking  an  antidepressant  during  the  entire  interview 
interval.  Up to 12 weeks of treatment with antidepressant medications may be needed to 
elicit  a  full  response  and  remission.110,  116,  117  There  is  evidence  indicating  that 
improvement  of  symptoms  of  minor  depression  can  occur  independent  of  treatment, 
which  is  why one  of  the  recommendations  for  treating  minor  depression  is  watchful 
waiting.118, 119  However it is possible that physicians may not re-address the depressive 
symptoms, or that the patient does not follow-up in the recommended amount of time. 
Once therapy is initiated it may likely be sub-optimal in duration.
The  observed  worsening  of  depressive  symptoms  in  participants  on  an 
antidepressant  may  be  due  to  confounding  by  indication.   Possible  indications  for 
antidepressant use can be a diagnosis of depression or related psychiatric disorders and 
depression severity.  It may be that physicians readily identified those patients who had a 
past medical history of depression or a high degree of depressive symptoms.  However, 
we controlled for the CESD score at the beginning of each interval for both the change 
score model and the transitions model. Indication bias can be controlled for by adjusting 
for  a  past  history  of  depressive  disorders  and  whether  the  patient  had  been  on 
antidepressants in the past.
5.4. The Future for Depression Treatment in Older Adults
While under recognition of depression in older adults continues to be a problem, 
there are new healthcare models that may promote the delivery of better mental health 
care  to  this  population.   Studies  have  shown  that  collaborative  care  models  that 
incorporate mental  health specialty treatment into primary care settings, such as those 
54
used in the Veterans’ Affairs Primary Care, IMPACT and PROSPECT studies, result in 
significant  improvements  in depression outcomes for older primary care patients.120-122 
The  Improving  Mood  Promoting  Access  to  Collaborative  Treatment  (IMPACT) 
randomized those with major depression or dysthymia to usual primary care treatment or 
a  collaborative  treatment  group  (e.g.  participants  were  assigned  a  case  manager  in 
addition  to  their  medication  and/or  counseling).   It  was  found  that  the  patient’s 
randomized  to  the  collaborative  treatment  group  had  better  outcomes  and  had  lower 
health care costs.121, 122  The Prevention of Suicide in Primary Care Elderly-Collaborative 
Trial study (PROSPECT) a specially trained master’s level health specialist works with 
the primary care physician to  identify and suggest treatments for depression in older 
patients, with a goal of  increasing adherence to pharmacological treatment.123-125 The goal 
of this study was to create a model that would reduce suicide in older adults and may be 
implemented  in  a  primary  care  medical  practices.   Suicidal  ideation  was  reduced 
regardless of depression severity in patients that participated in the PROSPECT trial.126
In 2007, an expert  panel  convened and strongly recommended that depression 
care management-modeled interventions be provided in primary care clinics.127  There is 
strong evidence that the collaborative care models described above are effective.  Future 
studies  may want  to  include more  training  for physicians  with respect  to  appropriate 
dosing and drug selection, more frequent and objective follow-up assessments, and the 
use of non-pharmacological  (i.e.  psychotherapy)  treatment..   In addition,  many of the 
studies described above were conducted in academic centers or clinics closely linked to 
an academic center, future studies would want to evaluate feasibility in a non-academic 
environment where resources may be limited.
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5.5. Study Limitations
Some limitations of the study should be considered when interpreting the results. 
First,  we  did  not  have  information  about  dosage,  frequency,  duration  or  changes  in 
medication.  However, we had information on who was taking an antidepressant at every 
18-month  time-point.   Also,  we had no information  about  adherence  to  medications. 
Future  studies  evaluating  antidepressant  effectiveness  in  older  adults  should  include 
specific information about the antidepressant medication,  dosage and adherence.  This 
information  would  allow  us  to  further  categorize  participants  as  having  aggressive 
treatment,  adequate  treatment,  or  undertreatment  of  their  depression.   Because 
information regarding participants’ depression status before the baseline interview was 
not available, we could not determine if participants’ first transition from a non-depressed 
to a depressed state represents incident depression.  We also do not know if a participant 
had  major  depression  in  the  past.   Consequently,  it  is  possible  that  the  depressed 
participants in our study that are not being treated have treatment resistant depression or 
depression that is not fully remitted.   However, to control for this,  we ran sensitivity 
analysis that excluded subjects who were depressed at baseline and obtained the same 
results. 29-31
We also did not assess non-pharmacologic treatments of depression.  Hence, our 
rates for depressant treatment may have been underestimates.  However, very few older 
adults see a psychotherapist for their depression and this likely would not affect a large 
proportion of our participants.  Future studies should include measures to assess these 
variables.
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Because our assessments were completed every 18-months,   it  is possible that 
some participants were treated for depression between two time time-points and achieved 
remission  before  the  next  assessment.  If  brief  treatments  and  remissions  occurred  at 
random with respect to the assessment intervals, we should have observed many of them, 
but would have underestimated the rate and effectiveness of the antidepressant treatment. 
Future studies would want to decrease the duration between interviews to 6-months to 1 
year.
Because our study participants were members of a single health plan,  initially 
nondisabled, and at least aged 70 years at baseline, the generalizability of our findings to 
other  older  adult  populations  may  be  questioned.   However,  the  demographic 
characteristics of our study population, including years of education, closely mirror those 
of persons 70 years  or older in New Haven County,  Connecticut,  which,  in turn,  are 
comparable to those in the United States as a whole, with the exception of race.  New 
Haven County has more non- Hispanic whites in this age group than in the United States 
(91% versus 84%).  Furthermore, generalizability depends not only on the characteristics 
of the study population but also on its stability over time.  The high participation rate, 
completeness of data collection, and low rate of attrition for reasons other than death all 
enhance the generalizability of our findings and at least partially offset the absence of a 
population-based sample.
Finally,  this  was  an epidemiologic  study and not a  clinical  trial  so inferences 
about treatment effectiveness must be made cautiously.   Again, an unexpected finding 
was that  antidepressant  treatment  was not associated with improvement  of depressive 
symptoms, but was associated with worsening of depressive symptoms.
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5.6. Conclusions and Recommendations
Our findings raise concerns about the effectiveness of antidepressant medications, 
as prescribed to older adults in clinical practice.  The results of this study indicate that 
more research is needed to understand the role of antidepressant medications in older 
adults with elevated depressive symptoms.
58
6  . References  
1. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of 
depression in late life. Consensus statement update. JAMA 1997;278(14):1186-90.
2. Lyness JM, Caine ED, King DA, Conwell Y, Duberstein PR, Cox C. Depressive 
Disorders and Symptoms in Older Primary Care Patients: One-Year Outcomes. Am J 
Geriatr Psychiatry 2002;10(3):275-82.
3. Ban TA. The Treatment of Depressed Geriatric Patients. American Journal of 
Psychotherapy 1978;32(1):93.
4. Blazer D, Williams CD. Epidemiology of dysphoria and depression in an elderly 
population. Am J Psychiatry 1980;137(4):439-44.
5. Gurland B DL, Cross P, Golden R. The epidemiology of depression and dementia 
in the elderly: the use of multiple indicators of these conditions. Proceedings 1980 69:37-
62.
6. Murrell SA, Himmelfarb S, Wright K. Prevalence of Depression  and its 
Correlates in Older Adults. Am J Epidemiol 1983;117(2):173-85.
7. Hybels CF, Pieper CF, Blazer DG. Sex differences in the relationship between 
subthreshold depression and mortality in a community sample of older adults. American 
Journal of Geriatric Psychiatry 2002;10(3):283-91.
8. Chopra MP, Zubritsky C, Knott K, et al. Importance of subsyndromal symptoms 
of depression in elderly patients. American Journal of Geriatric Psychiatry 
2005;13(7):597-606.
9. Horowitz A, Reinhardt JP, Kennedy GJ. Major and subthreshold depression 
among older adults seeking vision rehabilitation services. American Journal of Geriatric 
Psychiatry 2005;13(3):180-7.
10. Lyness JM. Naturalistic outcomes of minor and subsyndromal depression in older 
primary care patients. International Journal of Geriatric Psychiatry 2008;9999(9999):n/a.
11. Cuijpers P, de Graaf R, van Dorsselaer S. Minor depression: risk profiles, 
functional disability, health care use and risk of developing major depression. Journal of 
Affective Disorders 2004;79(1-3):71-9.
12. Penninx BW, Geerlings SW, Deeg DJ, van Eijk JT, van Tilburg W, Beekman AT. 
Minor and major depression and the risk of death in older persons.[see comment]. 
Archives of General Psychiatry 1999;56(10):889-95.
13. Unutzer J, Patrick DL, Marmon T, Simon GE, Katon WJ. Depressive Symptoms 
and Mortality in a Prospective Study of 2,558 Older Adults. Am J Geriatr Psychiatry 
2002;10(5):521-30.
14. Ariyo AA, Haan M, Tangen CM, et al. Depressive Symptoms and Risks of 
Coronary Heart Disease and Mortality in Elderly Americans. Circulation 
2000;102(15):1773-9.
15. Carnethon MR, Biggs ML, Barzilay JI, et al. Longitudinal association between 
depressive symptoms and incident type 2 diabetes mellitus in older adults: the 
cardiovascular health study. Archives of Internal Medicine 2007;167(8):802-7.
16. Koenig HG. Depression in hospitalized older patients with congestive heart 
failure. General Hospital Psychiatry 1998;20(1):29-43.
17. Yang Y, George LK. Functional disability, disability transitions, and depressive 
symptoms in late life. Journal of Aging & Health 2005;17(3):263-92.
59
18. Saydah SH, Brancati FL, Golden SH, Fradkin J, Harris MI. Depressive symptoms 
and the risk of type 2 diabetes mellitus in a US sample. Diabetes Metab Res Rev 
2003;19(3):202-8.
19. Machado GPM, Gignac MAM, Badley EM. Participation restrictions among older 
adults with osteoarthritis: a mediated model of physical symptoms, activity limitations, 
and depression. Arthritis Rheum 2008;59(1):129-35.
20. Conwell YMD, Lyness JMMD, Duberstein PP, et al. Completed Suicide Among 
Older Patients in Primary Care Practices: A Controlled Study. Journal of the American 
Geriatrics Society 2000;48(1):23-9.
21. Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population-
based sample of depressed elderly patients. Archives of General Psychiatry 
2003;60(9):897-903.
22. Stein MB, Cox BJ, Afifi TO, Belik S-L, Sareen J. Does co-morbid depressive 
illness magnify the impact of chronic physical illness? A population-based perspective. 
Psychological Medicine 2006;36(5):587-96.
23. Luppa M, Heinrich S, Matschinger H, et al. Direct costs associated with 
depression in old age in Germany. Journal of Affective Disorders 2008;105(1-3):195-
204.
24. Harman JS, Reynolds CF, III. Removing the barriers to effective depression 
treatment in old age. Journal of the American Geriatrics Society Vol 48(8) Aug 2000, 
1012-1013 2000.
25. Katon W. Will improving detection of depression in primary care lead to 
improved depressive outcomes?[comment]. General Hospital Psychiatry 1995;17(1):1-2.
26. Unützer J, Katon W, Sullivan M, Miranda J. Treating Depressed Older Adults in 
Primary Care: Narrowing the Gap between Efficacy and Effectiveness. The Milbank 
Quarterly 1999;77(2):225-56.
27. Thompson TL, 2nd, Mitchell WD, House RM. Geriatric psychiatry patients' care 
by primary care physicians. Psychosomatics 1989;30(1):65-72.
28. Gallo JJ, Anthony JC, Muthen BO. Age differences in the symptoms of 
depression: a latent trait analysis. J Gerontol 1994;49(6):P251-64.
29. Unutzer J, Simon G, Belin TR, Datt M, Katon W, Patrick D. Care for depression 
in HMO patients aged 65 and older.[see comment]. Journal of the American Geriatrics 
Society 2000;48(8):871-8.
30. Luber MP, Meyers BS, Williams-Russo PG, et al. Depression and service 
utilization in elderly primary care patients. American Journal of Geriatric Psychiatry 
2001;9(2):169-76.
31. Unutzer J, Katon W, Russo J, et al. Patterns of care for depressed older adults in a 
large-staff model HMO. American Journal of Geriatric Psychiatry 1999;7(3):235-43.
32. Givens JL, Datto CJ, Ruckdeschel K, et al. Older Patients' Aversion to 
Antidepressants: A Qualitative Study. J Gen Intern Med 2006;21:146-51.
33. McCormick WC, Inui, T. S., Roter, D. L. Interventions in physician-elderly 
patient interactions. Research in Aging 1996;18:103–36.
34. Beisecker AE. Older persons' medical encounters and their outcomes. . Research 
on Aging 1996;18:9-31.
35. Haug MR. Elements in physician/patient interactions in late life. Research in 
Aging 1996;18:32-51.
60
36. Kennedy GJ, Marcus P. Use of antidepressants in older patients with co-morbid 
medical conditions: guidance from studies of depression in somatic illness. Drugs & 
Aging 2005;22(4):273-87.
37. Williams-Russo P. Barriers to diagnosis and treatment of depression in primary 
care. American Journal of Geriatric Psychiatry 1996;4 (Suppl. 1): S84–S90.
38. Phifer JF, Murrell SA. Etiologic Factors in the Onset of Depressive Symptoms in 
Older Adults. Journal of Abnormal Psychology 1986;95(3):282-91.
39. Oxman TE, Hull JG. Social support and treatment response in older depressed 
primary care patients. Journals of Gerontology Series B-Psychological Sciences & Social 
Sciences 2001;56(1):P35-45.
40. Callahan CM, Nienaber NA, Hendrie HC, Tierney WM. Depression of elderly 
outpatients: primary care physicians' attitudes and practice patterns. J Gen Intern Med 
1992;7(1):26-31.
41. Williams JW, Jr., Mulrow CD, Kroenke K, et al. Case-finding for depression in 
primary care: a randomized trial. Am J Med 1999;106(1):36-43.
42. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two Shorter Forms of 
the CES-D Depression Symptoms Index. J Aging Health 1993;5(2):179-93.
43. Beekman AT DD, Van  Limbeek J, Braam AW, De Vries MZ, Van Tilburg W. 
Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): 
results from a community-based sample of older subjects in The Netherlands. 
Psychological Medicine 1997;27(1):231-5.
44. Hustey FM, Smith MD. A depression screen and intervention for older ED 
patients. Am J Emerg Med 2007;25(2):133-7.
45. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for Depression in Adults: 
A Summary of the Evidence for the U.S. Preventive Services Task Force. Ann Intern 
Med 2002;136(10):765-76.
46. Glasser M, Gravdal JA. Assessment and treatment of geriatric depression in 
primary care settings. Archives of Family Medicine 1997;6(5):433-8.
47. Blanchard MR, Waterreus A, Mann AH. The nature of depression among older 
people in inner London, and the contact with primary care. British Journal of Psychiatry 
1994;164(3):396-402.
48. Callahan CM, Dittus RS, Tierney WM. Primary care physicians' medical decision 
making for late-life depression. J Gen Intern Med 1996;11(4):218-25.
49. Gallo JJ, Ryan SD, Ford DE. Attitudes, Knowledge, and Behavior of Family 
Physicians Regarding Depression in Late Life. Arch Fam Med 1999;8(3):249-56.
50. Olfson M, Pincus HA. Outpatient psychotherapy in the United States, I: Volume, 
costs, and user characteristics. Am J Psychiatry 1994;151(9):1281-8.
51. Hendriks GJOV, R. C.; Keijsers, G. P. J.; Hoogduin, C. A. L.; van Balkom, A. J. 
L. M. Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review 
and meta-analysis. Acta Psychiatrica Scandinavica 2008;117(6):403-11.
52. Haykal RF, Akiskal HS. The long-term outcome of dysthymia in private practice: 
clinical features, temperament, and the art of management. J Clin Psychiatry 
1999;60(8):508-18.
53. Mamdani MM, Parikh SV, Austin PC, Upshur RE. Use of antidepressants among 
elderly subjects: trends and contributing factors.[see comment]. American Journal of 
Psychiatry 2000;157(3):360-7.
61
54. Reynolds CF, 3rd, Lebowitz BD. What are the best treatments for depression in 
old age? Harv Ment Health Lett 1999;15(12):8.
55. Ganguli M, Mulsant B, Richards S, Stoehr G, Mendelsohn A. Antidepressant use 
over time in a rural older adult population: the MoVIES Project.[see comment]. Journal 
of the American Geriatrics Society 1997;45(12):1501-3.
56. Blazer DG, Hybels CF, Fillenbaum GG, Pieper CF. Predictors of Antidepressant 
Use Among Older Adults: Have They Changed Over Time? Am J Psychiatry 
2005;162(4):705-10.
57. Moore JD, Bona JR. Depression and dysthymia. Med Clin North Am 
2001;85(3):631-44.
58. Unutzer J. Diagnosis and treatment of older adults with depression in primary 
care. Biol Psychiatry 2002;52(3):285-92.
59. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the 
upcoming crisis in geriatric mental health: research agenda for the next 2 decades. 
Archives of General Psychiatry 1999;56(9):848-53.
60. Salzman C, Wong E, Wright BC. Drug and ECT treatment of depression in the 
elderly, 1996-2001: a literature review. Biol Psychiatry 2002;52(3):265-84.
61. Gaynes BN, Rush AJ, Trivedi MH, et al. Primary versus specialty care outcomes 
for depressed outpatients managed with measurement-based care: results from STAR*D. 
J Gen Intern Med 2008;23(5):551-60.
62. Gaynes BN, Rush AJ, Trivedi M, et al. A direct comparison of presenting 
characteristics of depressed outpatients from primary vs. specialty care settings: 
preliminary findings from the STAR*D clinical trial. General Hospital Psychiatry 
2005;27(2):87-96.
63. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The 
STAR*D study: treating depression in the real world. Cleve Clin J Med 2008;75(1):57-
66.
64. Kozel FA, Trivedi MH, Wisniewski SR, et al. Treatment outcomes for older 
depressed patients with earlier versus late onset of first depressive episode: a Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) report. American Journal of 
Geriatric Psychiatry 2008;16(1):58-64.
65. Cain RA. Navigating the Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) study: practical outcomes and implications for depression 
treatment in primary care. Prim Care;34(3):505-19.
66. Alexander JL, Richardson G, Grypma L, Hunkeler EM. Collaborative depression 
care, screening, diagnosis and specificity of depression treatments in the primary care 
setting. Expert rev 2007;7(11 Suppl):S59-80.
67. Kennedy SH, Giacobbe P. Treatment resistant depression--advances in somatic 
therapies. Ann Clin Psychiatry 2007;19(4):279-87.
68. Freudenstein U, Jagger C, Arthur A, Donner-Banzhoff N. Treatments for late life 
depression in primary care--a systematic review. Fam Pract 2001;18(3):321-7.
69. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial 
comparing sertraline and citalopram in patients with major depression treated in general 
practice. International Clinical Psychopharmacology 1997;12(6):323-31.
70. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-
blind, controlled, multicentre, phase III trial in patients with unipolar major depression 
62
treated in general practice. International Clinical Psychopharmacology 1996;11(2):129-
36.
71. Williams JW, Jr., Barrett J, Oxman T, et al. Treatment of dysthymia and minor 
depression in primary care: A randomized controlled trial in older adults.[see comment]. 
JAMA 2000;284(12):1519-26.
72. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability 
of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet;In 
Press, Corrected Proof.
73. Montagnier D B-GP, Jacqmin-Gadda H, Dartigues JF, Rainfray M, Peres K, 
Lechevallier-Michel N, Fourrier-Reglat A. Evolution of prevalence of depressive 
symptoms and antidepressant use between 1988 and 1999 in a large sample of older 
French people: Results from the Personnes Agees Quid Study. . J Am Geriatr Soc 
2006;54(12):1839-45.
74. Blazer DG, Hybels CF, Simonsick EM, Hanlon JT. Marked Differences in 
Antidepressant Use by Race in an Elderly Community Sample: 1986-1996. Am J 
Psychiatry 2000;157(7):1089-94.
75. Callahan CM, Hendrie HC, Dittus RS, Brater D, et al. Improving treatment of late 
life depression in primary care: A randomized clinical trial. Journal of the American 
Geriatrics Society 1994;42(8):839-46.
76. Schulberg HC, Mulsant B, Schulz R, Rollman BL, Houck PR, Reynolds CF, 3rd. 
Characteristics and course of major depression in older primary care patients. Int J 
Psychiatry Med 1998;28(4):421-36.
77. Cole MG, Bellavance F, Mansour A. Prognosis of depression in elderly 
community and primary care populations: a systematic review and meta-analysis. 
American Journal of Psychiatry 1999;156(8):1182-9.
78. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective 
Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. N Engl J 
Med 2008;358(3):252-60.
79. Kirsch I DB, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial 
severity and antidepressant benefits: a meta-analysis of data submitted
to the Food and Drug Administration. PLoS Med 2008;5(2):E45.
80. Gopinath S, Katon WJ, Russo JE, Ludman EJ. Clinical factors associated with 
relapse in primary care patients with chronic or recurrent depression. Journal of Affective 
Disorders 2007;101(1-3):57-63.
81. Klinkman MS, Schwenk TL, Coyne JC. Depression in primary care--more like 
asthma than appendicitis: the Michigan Depression Project. Can J Psychiatry 
1997;42(9):966-73.
82. Barry LC, Allore HG, Guo Z, Bruce ML, Gill TM. Higher burden of depression 
among older women: the effect of onset, persistence, and mortality over time. Archives of 
General Psychiatry 2008;65(2):172-8.
83. Gill TM, Desai MM, Gahbauer EA, Holford TR, Williams CS. Restricted Activity 
among Community-Living Older Persons: Incidence, Precipitants, and Health Care 
Utilization. Ann Intern Med 2001;135(5):313-21.
84. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state" : A practical method 
for grading the cognitive state of patients for the clinician. Journal of Psychiatric 
Research 1975;12(3):189-98.
63
85. Hardy SE, Dubin JA, Holford TR, Gill TM. Transitions between States of 
Disability and Independence among Older Persons. Am J Epidemiol 2005;161(6):575-84.
86. Mouret J, Lemoine P, Minuit MP, Benkelfat C, Renardet M. Effects of trazodone 
on the sleep of depressed subjects — a polygraphic study. Psychopharmacology 
1988;95(1):S37-S43.
87. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum 
2005;20(8):533-59.
88. Becker PM. Pharmacologic and nonpharmacologic treatments of insomnia. 
Neurol Clin 2005;23(4):1149-63.
89. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the 
literature. Drugs 2005;65(7):927-47.
90. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain.[update of Cochrane 
Database Syst Rev. 2005;(3):CD005454; PMID: 16034979]. Cochrane Database Syst 
Rev 2007(4):CD005454.
91. Kohout FJ BL, Evans DA, Cornoni-Huntley J. . Two shorter forms of the CES-D 
(Center for Epidemiological Studies Depression) depression symptoms index. Journal of 
Aging Health 1993;5(2):179-93.
92. Huisani BA, Neff, J. A., Harrington, J. B., Hughes, M. D., & Stone, R. H. 
Depression in rural communities: Validating the CES-D scale. . Journal of Community 
Psychology 1980;8:20-7.
93. Myers JK, & Weissman, M. M. . Use of a self-report symptom scale to detect 
depression in a community sample. American Journal of Psychiatry 1980;137:1081-4.
94. Inc. SI. Statistical Analysis System, Version 9.1. 2002.
95. Penninx BW, Deeg DJ, van Eijk JT, Beekman AT, Guralnik JM. Changes in 
depression and physical decline in older adults: a longitudinal perspective. Journal of 
Affective Disorders 2000;61(1-2):1-12.
96. Ostir GV, Ottenbacher KJ, Markides KS. Onset of frailty in older adults and the 
protective role of positive affect. Psychology & Aging 2004;19(3):402-8.
97. Skoog I NL, Landahl S, Steen B. Mental disorders and the use of psychotropic 
drugs in an 85-year-old urban population. . Int Psychogeriatr 1993;5:33-48.
98. Lakey SL, Gray SL, Ciechanowski P, Schwartz S, Logerfo J. Antidepressant use 
in nonmajor depression: secondary analysis of a program to encourage active, rewarding 
lives for seniors (PEARLS), a randomized controlled trial in older adults from 2000 to 
2003. Am J Geriatr Pharmacother 2008;6(1):12-20.
99. Unutzer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 
1,801 depressed older adults in primary care. Journal of the American Geriatrics Society 
2003;51(4):505-14.
100. Sonnenberg CM, Beekman ATF, Deeg DJH, an Tilburg V. Drug treatment in 
depressed elderly in the Dutch community. International Journal of Geriatric Psychiatry 
2003;18(2):99-104.
101. Sonnenberg CM, Deeg DJH, Comijs HC, van Tilburg W, Beekman ATF. Trends 
in antidepressant use in the older population: Results from the LASA-study over a period 
of 10 years. Journal of Affective Disorders 2008;111(2-3):299-305.
102. Luppa M, Heinrich S, Angermeyer MC, Knight H-H, Riedel-Heller SG. 
Healthcare costs associated with recognized and unrecognized depression in old age. Int 
Psychogeriatr 2008;20(06):1219-29.
64
103. Buckley MR, Lachman VD. Depression in older patients: recognition and 
treatment. Jaapa 2007;20(8):34-41.
104. Simon GE, VonKorff M. Recognition, Management, and Outcomes of Depression 
in Primary Care. Arch Fam Med 1995;4(2):99-105.
105. Stek ML, Gussekloo J, Beekman ATF, van Tilburg W, Westendorp RGJ. 
Prevalence, correlates and recognition of depression in the oldest old: the Leiden 85-plus 
study. Journal of Affective Disorders 2004;78(3):193-200.
106. Pepersack T, De Breucker S, Mekongo Y-PN, Rogiers A, Beyer I. Correlates of 
unrecognized depression among hospitalized geriatric patients. J Psychiatr Pract 
2006;12(3):160-7.
107. Garrard J, Rolnick SJ, Nitz NM, et al. Clinical detection of depression among 
community-based elderly people with self-reported symptoms of depression. Journals of 
Gerontology Series A-Biological Sciences & Medical Sciences 1998;53(2):M92-101.
108. Aragones E, Pinol JL, Labad A, Folch S, Melich N. Detection and management of 
depressive disorders in primary care in Spain. Int J Psychiatry Med 2004;34(4):331-43.
109. Barkin RL, Schwer WA, Barkin SJ. Recognition and management of depression 
in primary care: a focus on the elderly. A pharmacotherapeutic overview of the selection 
process among the traditional and new antidepressants. Am J Ther 2000;7(3):205-26.
110. Unutzer J. Late-Life Depression. N Engl J Med 2007;357(22):2269-76.
111. Bosworth HB, Voils CI, Potter GG, Steffens DC. The effects of antidepressant 
medication adherence as well as psychosocial and clinical factors on depression outcome 
among older adults. International Journal of Geriatric Psychiatry 2008;23(2):129-34.
112. Cowan MJ, Freedland KE, Burg MM, et al. Predictors of treatment response for 
depression and inadequate social support--the ENRICHD randomized clinical trial. 
Psychother Psychosom 2008;77(1):27-37.
113. Zivin K, Kales HC. Adherence to depression treatment in older adults: a narrative 
review. Drugs & Aging 2008;25(7):559-71.
114. Fitch K, Molnar FJ, Power B, Wilkins D, Man-Son-Hing M. Antidepressant use 
in older people: family physicians' knowledge, attitudes, and practices. Can Fam 
Physician 2005;51(1):80-1.
115. Simon GE, Lin EH, Katon W, et al. Outcomes of "inadequate" antidepressant 
treatment.[see comment]. J Gen Intern Med 1995;10(12):663-70.
116. Moride YdF, Guillaume Galbaud; Monette, Johanne; Ducruet, Thierry; Boivin, 
Jean-François; Nathalie Champoux, MD; Crott, Ralph. Suboptimal Duration of 
Antidepressant Treatments in the Older Ambulatory Population of Quebec: Association 
with Selected Physician Characteristics. Journal of the American Geriatrics Society 
2002;50(8):1365-71.
117. Wang PSMDD, Schneeweiss SMDS, Brookhart MAP, et al. Suboptimal 
Antidepressant Use in the Elderly. [Article]. Journal of Clinical Psychopharmacology 
April 2005;25(2):118-26.
118. Oxman TE, Sengupta A. Treatment of Minor Depression. American Journal of 
Geriatric Psych 2002;10(3):256-64.
119. Baldwin RC, Anderson D, Black S, et al. Guideline for the management of late-
life depression in primary care. International Journal of Geriatric Psychiatry 
2003;18(9):829-38.
65
120. Hedrick SC, Chaney EF, Felker B, et al. Effectiveness of collaborative care 
depression treatment in Veterans' Affairs primary care.[see comment]. J Gen Intern Med 
2003;18(1):9-16.
121. Katon WJ, Schoenbaum M, Fan M-Y, et al. Cost-effectiveness of improving 
primary care treatment of late-life depression. Archives of General Psychiatry 
2005;62(12):1313-20.
122. Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-
life depression in the primary care setting: a randomized controlled trial.[see comment]. 
JAMA 2002;288(22):2836-45.
123. Bogner HR, Lin JY, Morales KH. Patterns of early adherence to the 
antidepressant citalopram among older primary care patients: the prospect study. Int J 
Psychiatry Med 2006;36(1):103-19.
124. Reynolds CF, 3rd, Degenholtz H, Parker LS, et al. Treatment as usual (TAU) 
control practices in the PROSPECT Study: managing the interaction and tension between 
research design and ethics. International Journal of Geriatric Psychiatry 2001;16(6):602-
8.
125. Alexopoulos GS, Katz IR, Bruce ML, et al. Remission in Depressed Geriatric 
Primary Care Patients: A Report From the PROSPECT Study. American Journal of 
Psychiatry Vol 162(4) Apr 2005, 718-724 2005.
126. Bruce ML, Ten Have TR, Reynolds CF, 3rd, et al. Reducing suicidal ideation and 
depressive symptoms in depressed older primary care patients: a randomized controlled 
trial.[see comment]. JAMA 2004;291(9):1081-91.
127. Steinman LE, Frederick JT, Prohaska T, et al. Recommendations for treating 
depression in community-based older adults. Am J Prev Med 2007;33(3):175-81.
